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The human organic cation transporter 1 (hOCT1) is a polyspecific transporter, 
primarily expressed in the liver, which is known to interact with a large number of 
structurally dissimilar compounds. Several clinically-relevant drugs, as well as some 
endogenous compounds and other xenobiotics have been shown to be transported by 
or inhibit hOCT1. Due to its hepatic expression and general ADME function, hOCT1 has 
been implicated in adverse drug events (ADEs), including drug-drug interactions. As 
such, multiple regulatory agencies recommend including hOCT1, in pre-clinical 
transporter interaction studies. Limited structural information is available for hOCT1, and 
recently, endogenous functions and substrate-dependent effects have been identified 
for close relatives of hOCT1. Taken together, these suggest a need for further scrutiny 
of hOCT1 structure-activity relationships for development of critical drug-transporter 
interaction studies.  
The hypothesis was developed that both endogenous and xenobiotic compounds 
modulate the functional activity of hOCT1 in a substrate-dependent manner through 
interaction with specific, but perhaps distinct ligand-binding domains within the 
transporter. The hypothesis was tested via the following specific aims: 1) investigate the 
effect of xenobiotics on endogenous substrate transport by hOCT1, 2) identify and 
characterize substrate-dependent interactions with hOCT1, and 3) examine the role of 
the extracellular loop domain of hOCT1 in substrate affinity and translocation. 
 In the first specific aim, dopamine and serotonin were identified as substrates for 




transport it at high capacity. Several clinically-relevant drugs inhibited hOCT1-mediated 
serotonin transport, and these results were capitulated in primary human hepatocytes. 
Combined data from this inhibition screen and those previously published by other 
groups suggested the possibility of substrate-dependent effects. 
 In specific aim two, substrate-dependent effects were screened for in a relatively 
new assay method, competitive counterflow (CCF). The CCF assay allowed for 
identification of novel substrates for hOCT1, including negatively-charged 
bromosulfophthalein (BSP). CCF results also identified numerous substrate-dependent 
effects which were explored further using computational (homology) modeling and 
ligand docking. Docking experiments identified three distinct binding sites within the 
hOCT1 homology model which explain several of the overserved substrate-dependent 
interactions, and supports previous claims that hOCT1 has a large substrate binding 
region versus a singular binding site and may be the reason for hOCT1’s polyspecificity. 
 In the final specific aim, an attempt was made to generate human and rat OCT1 
chimeric proteins. The goal of this study was to examine the role of the extracellular 
loop (ECL) domain in the observed differences in substrate affinity between species. 
Issues during the cloning process prevented the completion of this aim. However, had 
the chimeras successfully been generated, important information relating hOCT1 
structure to its function could have been collected. 
 This dissertation demonstrates that hOCT1 possesses important endogenous 
function and exhibits substrate-dependent effects, while also revealing important 




improving pre-clinical trials for new drugs in the hope of identifying and preventing 











TABLE OF CONTENTS IN BRIEF 
Acceptance Page ............................................................................................................ ii 
Abstract ........................................................................................................................... iii 
Dedication ...................................................................................................................... vi 
Table of Contents in Brief ............................................................................................... vii 
Table of Contents Expanded ......................................................................................... viii 
List of Tables .................................................................................................................. xi 
List of Figures ................................................................................................................. xii 




TABLE OF CONTENTS 
 : INTRODUCTION ......................................................................................................... 1 CHAPTER 1
1.1 Introduction to Pharmacokinetics ........................................................................... 2 
1.2 Transporters Involved in ADME ............................................................................. 3 
1.3 Introduction to Organic Cation Transporter 1 ......................................................... 6 
1.3.1 Cloning and Functional Characterization of OCT1 ........................................... 6 
1.3.2 hOCT1 Expression and Tissue Distribution..................................................... 7 
1.3.3 Molecular Regulation of hOCT1 ...................................................................... 9 
1.3.3.1 Regulation of hOCT1 Expression ................................................. 12 
1.3.3.2 hOCT1 Functional Regulation ...................................................... 14 
1.3.4 hOCT1 Structure ........................................................................................... 15 
1.3.5 Mechanisms of Transport for hOCT1 ............................................................. 18 
1.3.6 hOCT1 Substrate and Inhibitor Specificity ..................................................... 20 
1.3.7 Clinical Significance and Polymorphisms of hOCT1 ...................................... 33 
1.4 Transporter-Mediated Adverse Drug Interactions ................................................ 37 
1.4.1 hOCT1-Mediated Drug-Drug Interactions ...................................................... 38 
1.5 Substrate-Dependent Effects of Drug Transporters ............................................. 40 
1.6 Specific Aims of this Dissertation ......................................................................... 43 
1.6.1 Specific Aim 1: Investigate the effect of xenobiotics on endogenous substrate 
transport by hOCT1 ....................................................................................... 44 
1.6.2 Specific Aim 2: Identify and characterize substrate-dependent interactions 
with hOCT1 ................................................................................................... 45 
1.6.3 Specific Aim 3: Examine the role of the extracellular loop domain of hOCT1 in 
substrate affinity and translocation ................................................................ 45 
 : COMMON DRUGS INHIBIT HUMAN OCT1-MEDIATED CHAPTER 2
NEUROTRANSMITTER UPTAKE ........................................................................ 47 
2.1 Introduction .......................................................................................................... 48 
2.2 Materials and Methods ......................................................................................... 49 
2.2.1 Materials ........................................................................................................ 49 




2.2.3 Transport Assays ........................................................................................... 50 
2.2.4 Western Blotting ............................................................................................ 51 
2.2.5 Kinetic Analysis .............................................................................................. 52 
2.2.6 IC50 Determination ......................................................................................... 52 
2.2.7 Statistical Analysis ......................................................................................... 53 
2.3 Results ................................................................................................................. 53 
2.3.1 Functional Characterization of Human OCT1 in Transiently-transfected 
HEK293 Cells ................................................................................................ 53 
2.3.2 hOCT1-mediated Neurotransmitter Transport ............................................... 53 
2.3.3 Kinetic Characterization of Serotonin Uptake by hOCT1 ............................... 56 
2.3.4 Inhibition of Serotonin Transport .................................................................... 58 
2.3.5 Serotonin transport and inhibition in primary human hepatocytes ................. 62 
2.4 Discussion ............................................................................................................ 64 
 : SUBSTRATE-DEPENDENT LIGAND INTERACTIONS WITH HUMAN CHAPTER 3
ORGANIC CATION TRANSPORTER 1 ............................................................. 70 
3.1 Introduction .......................................................................................................... 71 
3.2 Materials and Methods ......................................................................................... 73 
3.2.1 Materials ........................................................................................................ 73 
3.2.2 Generation and Culture of Stable Cell Lines .................................................. 73 
3.2.3 Transport Assays ........................................................................................... 74 
3.2.4 Determination of Kinetic Parameters ............................................................. 78 
3.2.5 Generation of a hOCT1 Homology Model ...................................................... 78 
3.2.6 Docking of Ligands into the hOCT1 Homology Model ................................... 80 
3.3 Results ................................................................................................................. 81 
3.3.1 Functional Validation of Generated hOCT1 Stable Transfectants ................. 81 
3.3.2 Substrate-dependent Interactions with hOCT1 as Determined by Competitive 
Counterflow ................................................................................................... 82 
3.3.3 Characterization of hOCT1-mediated Bromosulfophthalein Uptake .............. 88 
3.3.4 Computational Modeling of Ligand Interactions ............................................. 88 




 : GENERATION OF HUMAN/RAT CHIMERIC OCT1 PROTEINS TO CHAPTER 4
EXAMINE THE ROLE OF THE EXTRACELLULAR LOOP DOMAIN IN 
SUBSTRATE AFFINITY AND SPECIFICITY .................................................. 103 
4.1 Introduction ........................................................................................................ 104 
4.2 Materials and Methods ....................................................................................... 107 
4.2.1 Materials ...................................................................................................... 107 
4.2.2 Primer Design .............................................................................................. 109 
4.3 Results ............................................................................................................... 109 
4.3.1 Generation of Human and Rat OCT1 Chimeric Proteins ............................. 109 
4.3.2 Insertion of His-tag into Human and Rat OCT1 DNA Sequences ................ 114 
4.4 Discussion .......................................................................................................... 122 
 : DISCUSSION AND FUTURE DIRECTIONS .................................................. 127 CHAPTER 5
5.1 Significance ........................................................................................................ 128 
5.2 Specific Aim 1 .................................................................................................... 129 
5.3 Specific Aim 2 .................................................................................................... 132 
5.4 Specific Aim 3 .................................................................................................... 134 
5.5 Future Directions ................................................................................................ 136 
REFERENCES ............................................................................................................ 139 






LIST OF TABLES 
Table 1.1      Human OCT1 mRNA and protein expression in various tissues .............. 10 
Table 1.2      Select drug substrates of hOCT1 ............................................................. 21 
Table 1.3      Other xenobiotic and model substrates of hOCT1 .................................... 24 
Table 1.4      Endogenous substrates of hOCT1 ........................................................... 25 
Table 1.5      Select inhibitors of hOCT1 ........................................................................ 26 
Table 1.6      Select hOCT1 variants and their functional consequences ...................... 34 
Table 3.1      Published Km/IC50 values and concentrations of test compounds ............ 76 
Table 4.1      Affinities of select substrates of human and rat OCT1 ........................... 105 
Table 4.2      Oligonucleotide primer sequences for addition of C-terminal His-tag to 
wild-type human and rat OCT1 .............................................................. 110 
Table 4.3      Troubleshooting of subcloning methods for generating human and rat 





LIST OF FIGURES 
Figure 1.1      Important drug transporters expressed in intestine, liver, kidney, and at 
the blood-brain barrier .............................................................................. 5 
Figure 1.2      Amino acid sequence and predicted membrane topology of hOCT1 ...... 17 
Figure 2.1      Time-dependent uptake of MPP+ by hOCT1 ........................................... 54 
Figure 2.2      Kinetics of hOCT1-mediated MPP+ uptake ............................................. 55 
Figure 2.3      Transport of serotonin, dopamine, and norepinephrine by hOCT1 ......... 57 
Figure 2.4      Kinetics of hOCT1-mediated serotonin transport .................................... 59 
Figure 2.5      Inhibition of serotonin transport by common drugs .................................. 60 
Figure 2.6      Concentration-dependent inhibition of serotonin uptake by  
hOCT1 .................................................................................................... 61 
Figure 2.7      Oligonucleotide primer sequences for addition of C-terminal His-tag to 
wild-type human and rat OCT1 ............................................................... 63 
Figure 3.1      Uptake of MPP+ and Serotonin by HEK-EV and-hOCT1 stable 
transfectants ........................................................................................... 83 
Figure 3.2      Time-dependent uptake and efflux of MPP+, serotonin, metformin, and 
TEA by hOCT1 ....................................................................................... 84 
Figure 3.3      Substrate-dependent ligand interactions as determined by competitive 
counterflow ............................................................................................. 87 
Figure 3.4      Bromosulfophthalein is a substrate of hOCT1 ......................................... 89 
Figure 3.5      Homology model of hOCT1 ..................................................................... 90 
Figure 3.6      Ligand structures docked into hOCT1 homology model .......................... 92 
Figure 3.7      Ligands docked in disparate pockets within hOCT1 homology model .... 96 
Figure 4.1      Schematic representation of human and rat OCT1 chimeric proteins ... 108 
Figure 4.2      Generation of human and rat OCT1 chimeric proteins .......................... 111 
Figure 4.3      PCR products from QuikChange II Site-Directed Mutagenesis kit method




Figure 4.4      PCR amplicons for human and rat OCT1-Cterm-His ............................ 116 
Figure 4.5      DNA isolated from bacterial colonies following ligation of pcDNA5/FRT 
and human and rat OCT1-Cterm-His .................................................... 118 





LIST OF ABBREVIATIONS 
ABC – ATP-binding cassette 
ADE – adverse drug event 
ADME – absorption, distribution, metabolism, and excretion 
AhR – aryl hydrocarbon receptor 
AMPK – adenosine monophosphate-activated protein kinase 
APDA – N-(4,4-azo-n-pentyl)-21-deoxyajmalinium 
APQ – N-(4,4-azo-n-pentyl)-quinuclidine 
ASP+ – 4-4-dimethylaminostyryl-N-methylpyridinium  
ATP – adenosine triphosphate 
AUC – area under the curve 
Β1 – beta1 adrenergic receptor 
β2 – beta2 adrenergic receptor 
BCA – bicinchoninic acid assay 
BCRP – breast cancer resistance protein 
BHM – build homology models 
Bmim – 1-butyl-3-methylimidazolium chloride 
BmPy – N-butyl-N-methylpyrrolidinium 
BPH – benign prostatic hyperplasia 
BSEP – bile salt efflux pump 
BSP – bromosulfophthalein 
CaM – calmodulin 
CaMKII – calmodulin-dependent kinase II 
CAR – constitutive androstane receptor 




CCF – competitive counterflow 
CDPCP – cis-diammine(pyridine)chloroplatinum(II) 
CHO – Chinese hamster ovary 
CL – cytoplasmic loop 
CLL – chronic lymphocytic leukemia 
Cmax – maximal plasma concentration 
CML – chronic myeloid leukemia 
DAT – dopamine transporter 
DDI – drug-drug interaction 
DHEAS – dehydroepiandrosterone sulfate 
DMSO – dimethylsulfoxide 
DOPE – discrete optimized protein energy 
DTP – Developmental Therapeutics Program 
E3S – estrone-3-sulfate 
E17βG – estradiol-17β-glucuronide 
ECL – extracellular loop 
EGCG – epigallocatechin gallate 
EMA – European Medicines Agency 
ENT – equilibrative nucleoside transporter 
EtOH – ethanol 
EV – empty vector 
FDA – Food and Drug Administration 
FRET – Förster resonance energy transfer/fluorescence resonance energy transfer 
FXR – farnesoid X receptor 




H2 – histamine H2 receptor  
HAART – highly active antiretroviral therapy 
HCC – hepatocarcinoma 
HEK – human embryonic kidney 
HEPES – 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV – human immunodeficiency virus 
HNF1 – hepatocyte nuclear factor 1 
HNF4α – hepatocyte nuclear factor 4α 
HTS – high-throughput screening 
IC50 – half maximal inhibitory concentration 
IND – investigational new drug 
IPTG – isopropyl β-D-1-thiogalacto-pyranoside 
LacY – lactose permease 
LB – Luria Bertani 
kD – kilodalton 
Km – Michaelis-Menten constant 
LacY – lactose permease 
MATE – multidrug and toxin extrusion protein 
MDMA – 3,4-methylenedioxymethamphetamine 
MDR1 – multidrug resistance protein 1; P-glycoprotein 
MeOH – methanol  
MFS – major facilitator superfamily 
mIBG – [123I]-meta-iodobenzylguanidine 
MPP+ – 1-methyl-4-phenylpyridinium 




mRNA – messenger RNA 
MRP – multidrug resistance-associated protein 
NASH – nonalcoholic steatohepatitis 
NBD-MTMA – N,N,N-trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino]  
ethanaminium 
NCI – National Cancer Institute 
NET – norepinephrine transporter 
NMN – N-1-methylnicotinamide 
NMR – nuclear magnetic resonance 
NRTI – nucleoside reverse transcriptase inhibitor 
NTCP – sodium/taurocholate co-transporting polypeptide 
OAT – organic anion transporter 
OATP – organic anion transporting polypeptide 
OCT – organic cation transporter 
OCTN – organic cation/carnitine transporter 
ORF – open reading frame 
PDB – Protein Data Bank 
P-gp – (see MDR1) 
PEPT- peptide transporter 
PGE2 – prostaglandin E2 
PiPT – Piriformospora indica phosphate transporter 
PKA – protein kinase A 
PKC – protein kinase C 
PKG – protein kinase G 




PXR – pregnane X receptor 
RACE – rapid amplification of cDNA ends 
rOCT1 – rat organic cation transporter 1 
RT-PCR – reverse transcription polymerase chain reaction 
SAR – structure-activity relationship 
SD – standard deviation 
SEM – standard error of the mean 
SERT – serotonin reuptake transporter 
SHP – small heterodimer partner 
SLC – solute carrier 
SLCO – solute carrier family of the OATPs 
SRC-1 – steroid receptor coactivator 1 
TBA – tetrabutylammonium 
TBE – tris/borate/EDTA 
TBuMA – tributylmethylammonium 
TCDD – dioxin; 2,3,7,8-tetrachlorodibenzo-p-dioxin 
TEA – tetraethylammonium 
THA – tetrahexylammonium 
TKI – tyrosine kinase inhibitor 
TM/TMD – transmembrane domain 
TEMA – triethylmethylammonium 
TMA – tetramethylammonium 
TPeA – tetrapentylammonium 
TPrA – tetrapropylammonium 




LIST OF APPENDICES 
Appendix I: Citations of published papers 













1.1 INTRODUCTION TO PHARMACOKINETICS 
The field of pharmacology can be loosely divided into two categories: 
pharmacodynamics, described as the effect(s) a drug exerts on the body, and 
pharmacokinetics, or the effect the body has on a drug. Pharmacokinetics describes 
how a drug is taken in, disbursed throughout the body, and expelled from the body. 
These processes are commonly referred to using the acronym ADME, which stands for 
absorption, distribution, metabolism, and excretion (Doogue and Polasek, 2013). These 
four factors collectively determine the disposition of a given drug in the body.  
The first step, absorption, is the means by which a drug gains access to the 
body. The most common route of drug administration is oral, and therefore absorption 
into the bloodstream via the intestine is a critical first step. The next step, distribution of 
the drug into various tissues of the body, is achieved through systemic circulation which 
allows for the delivery of drug to the target tissue (where it will exert the desired effects), 
as well as into detoxifying organs, most notably the liver and kidneys, for metabolism 
and excretion. It is estimated that nearly 60% of prescribed drugs must undergo hepatic 
metabolism (Cascorbi, 2006) to convert the drug into a more hydrophillic entity before it 
can be excreted. The final component of drug disposition described by ADME is 
excretion, or the process by which a drug or metabolite leaves the body. The most 
common routes of excretion are through the kidneys, or the intestines by way of the 
liver. Collectively, the processes in ADME are crucial to drug efficacy and detoxification. 
Generally, a required process for all of these steps is the passing of drug 




pass through cell membranes: passive diffusion, facilitated diffusion, and active 
transport. Passive diffusion is the movement of molecules through a cell membrane 
from high concentration to low concentration without the aid of carriers or energy 
expenditure; whereas facilitated diffusion involves the passage of molecules across a 
membrane along a concentration gradient by utilizing a carrier protein, or transporter. 
Active transport moves molecules across cell membranes, via a transport protein, 
against a concentration gradient, and therefore energy expenditure, usually in the form 
of ATP hydrolysis, is required. 
Several factors determine a molecule’s ability to passively diffuse across the 
plasma membrane, including size and lipophilicity. Due to the selectively permeable 
nature of cell membranes, many drugs are incapable of entering cells via passive 
diffusion, and thus must enter cells via facilitated diffusion or active transport. As a 
result, there is an ever-increasing appreciation for the role of transporters in ADME. 
 
1.2 TRANSPORTERS INVOLVED IN ADME 
Transporters expressed at the cell membrane have been described as 
“gatekeepers” that govern selective cellular permeability (Kaback, et al., 2001, Sprowl, 
et al., 2016). They regulate uptake and efflux of essential cellular components, including 
amino acids, sugars, nucleosides, and inorganic ions (Kaback, et al., 2001, Wu, et al., 
2011). Transporters are also largely responsible for the movement of pharmaceutical 




to drugs (Borst and Elferink, 2002, Hillgren, et al., 2013, International Transporter, et al., 
2010, Nies, et al., 2011b). 
Transporters are ubiquitously expressed throughout the body. However, drug 
transporters are generally concentrated in tissues with barrier functions, namely the 
liver, kidneys, intestine, and brain, the same tissues highly involved in ADME (You and 
Morris, 2007). A summary of transporters expressed in these tissues that have been 
identified as important in drug disposition can be seen in Figure 1.1 (Hillgren, et al., 
2013, International Transporter, et al., 2010, You and Morris, 2007). These transporters 
are divided into two large superfamilies of transporters: ATP-binding cassette (ABC) 
and solute carrier (SLC) transporters.  
ABC transporters generally function as effluxers, pumping substrates out of the 
cell against their concentration gradients via active transport using energy derived from 
ATP hydrolysis. Important drug transporters in the ABC superfamily include the 
multidrug resistance protein (MDR1; also known as P-glycoprotein, or P-gp), multidrug 
resistance-associated proteins (MRPs), and breast cancer resistance protein (BCRP) 
(Hillgren, et al., 2013, You and Morris, 2007). 
SLC transporters operate as facilitated diffusion carriers and are generally influx 
transporters, though some function as exchangers or effluxers (Koepsell, 2015, You and 
Morris, 2007). SLC transporters which have been identified as important in drug 
disposition include organic cation transporters (OCTs), organic cation/carnitine 
transporters (OCTNs), multidrug and toxin extrusion proteins (MATEs), organic anion 





Figure 1.1. Important drug transporters expressed in intestine, liver, kidney, and at 
the blood-brain barrier. Relevant ABC (red) and SLC/SLCO (blue) transporters 
expressed in enterocytes, hepatocytes, kidney proximal tubule cells, and brain capillary 
endothelial cells. Schematic adapted from (Hillgren, et al., 2013, You and Morris, 2007, 




sodium/taurocholate co-transporting polypeptide (NTCP), equilibrative nucleoside 
transporters (ENTs), and peptide transporters (PEPTs) (Hillgren, et al., 2013, You and 
Morris, 2007). 
The work presented in this dissertation focuses on organic cation transporters, 
and specifically hOCT1 (SLC22A1). 
 
1.3 INTRODUCTION TO ORGANIC CATION TRANSPORTER 1 
Organic cation transporter 1 (OCT1) is a multispecific transporter belonging to 
the SLC22 superfamily (identified by gene name SLC22A1). Homologs exist in humans, 
several species of rodents, insects, and bacteria. OCT1 is expressed in several tissues 
and is involved in the transport of numerous clinically-relevant drugs and endogenous 
compounds. 
1.3.1 Cloning and Functional Characterization of OCT1 
The first OCT1 homolog was isolated from rat kidney using functional expression 
cloning (rOCT1; Grundemann, et al., 1994). They reported the identification of a novel 
556 amino acid transmembrane protein which demonstrated saturable uptake of model 
cation tetraethylammonium (TEA) in Xenopus laevis oocytes. Uptake of TEA was 
independent of sodium and potassium concentration, as well as alterations to intra- and 
extracellular pH, but appeared to be dependent on membrane potential. Transport was 
also inhibited by several structurally dissimilar hydrophobic and hydrophilic cations. 




phenylpyridinium (MPP+), and choline as additional substrates (Busch, et al., 1996b). It 
was also determined that rOCT1 could translocate electrical charge across the 
membrane and transport function could be measured using electrophysiology 
techniques, which lead to the classification of rOCT1 as an electrogenic transporter 
(Busch, et al., 1996b). 
Shortly after isolation of rOCT1, two groups independently cloned human OCT1 
(hOCT1) using homology screening of human kidney and liver cDNA libraries 
(Gorboulev, et al., 1997) and human liver mRNA subjected to RT-PCR and RACE 
(Zhang, et al., 1997b). The resultant cDNAs encoded proteins of 553 and 554 amino 
acids, respectively, and shared a 78% homology with rOCT1. Like rOCT1, hOCT1 
demonstrated saturable transport of MPP+, NMN, and TEA, which was inhibited by both 
small and large organic cations, though some inhibitor-specificity was observed 
(Gorboulev, et al., 1997, Zhang, et al., 1997b). Consistent with rOCT1, hOCT1 transport 
rates did not show a significant difference when pH was varied, but did appear to be 
dependent on membrane potential (Zhang, et al., 1997b). It was reasoned that human 
and rat OCT1 functioned by similar mechanisms, though with important species-
dependent differences in kinetics of interactions (Zhang, et al., 1997b, Zhang, et al., 
1998). 
1.3.2 hOCT1 Expression and Tissue Distribution 
When first cloned, it was determined that hOCT1 was predominantly expressed 
in the liver (Gorboulev, et al., 1997, Zhang, et al., 1997b). Immunohistochemistry 




membranes of hepatocytes (Nies, et al., 2008, Nies, et al., 2009). Subsequent studies 
demonstrated expression of hOCT1 expression at the apical membrane of kidney 
proximal and distal tubules (Nies, et al., 2008, Tzvetkov, et al., 2009), on the luminal 
side of brain microvascular endothelial cells (Lin, et al., 2010), at the apical membrane 
of airway epithelia (Lips, et al., 2005), and at the luminal and lateral membranes of the 
small intestine (Muller, et al., 2005). hOCT1 mRNA is found in several other tissues, 
including heart, pancreas, spleen, stomach, skeletal muscle, large intestine, adipose, 
adrenal glands, thyroid, salivary glands, bone marrow, thymus, ovaries, uterus, 
placenta, mammary glands, prostate, and testis (Hilgendorf, et al., 2007, Jung, et al., 
2008, Moreno-Navarrete, et al., 2011, Nies, et al., 2009, Nishimura and Naito, 2005, 
Zhang, et al., 1997b). 
Aberrant expression of hOCT1 is observed in various disease states. Leukocytes 
and lymphocytes from chronic myeloid leukemia (CML) and chronic lymphocytic 
leukemia (CLL) patients exhibited significantly higher levels of hOCT1 expression than 
control cells, which expressed very little (Gupta, et al., 2012, Thomas, et al., 2004). 
Additionally, hOCT1 expression was elevated and correlated with disease stage in 
lymphocytes isolated from HIV-infected patients, while expression in cells from healthy 
controls was negligible (Jung, et al., 2008). In certain colorectal cancer patients, hOCT1 
mRNA expression was found to be significantly increased compared to normal samples 
(Zhang, et al., 2006). Interestingly, hepatic expression of hOCT1 is decreased in 
advanced hepatocarcinoma (HCC) and cholangiocarcinoma (CC) patients (Heise, et al., 
2012, Herraez, et al., 2013, Schaeffeler, et al., 2011), as well as those suffering from 




states are likely due to altered expression or function of transcription factors known to 
regulate hOCT1 (see section 1.3.3). A summary of hOCT1 expression can be found in 
Table 1.1. 
Several groups have characterized the expression profiles of hOCT1 in cultured 
cell lines. hOCT1 expression is observed in: SK-MG-1 and Ski-1 cells derived from 
human glioma; human hepatoma cell lines Hep3b, Huh7, HepG2 and HepaRG; Caki-1 
cells derived from human kidney carcinoma; human colon adenocarcinoma cell lines 
Caco-2, LS180, DLD, SW620, and HT29; human colorectal carcinoma cell lines 
HCT116 and RKO; JAR, a human placenta choriocarcinoma cell line; hCMEC/D3, an 
immortalized human brain endothelial cell line; TOV2223G cells, an ovarian cancer cell 
line; and human leukemia, lymphoma, or lymphoblastoid cell lines MT2, MT4, 
Molt4/CCR5, Hut78, A3F7, CEM13, KYO1, LAMA84, KCL22, K562, Karpas-422, Raji, 
SUDHL-4, JURKAT, and L-428 (Andreev, et al., 2016, Dickens, et al., 2012, Gupta, et 
al., 2012, Hayer-Zillgen, et al., 2002, Heise, et al., 2012, Hilgendorf, et al., 2007, Le 
Vee, et al., 2006, Minuesa, et al., 2008, Muller, et al., 2005, Thomas, et al., 2004, 
Zhang, et al., 2000, Zhang, et al., 2006). Expression profiles for hOCT1 in cultured cell 
lines appear to be similar to those of the human tissues they’re derived from, whether 
under normal or disease conditions, and therefore are useful models for exploring drug 
transport under normal physiological conditions or in disease states. 
1.3.3 Molecular Regulation of hOCT1 
hOCT1 regulation is two-fold: regulation of expression, and regulation of function. 





Table 1.1. Human OCT1 mRNA and protein expression in various tissues. 
Normal 
Expression 
Tissue mRNA Protein Reference 
Liver + + 
Dickens, et al., 2012, Gorboulev, et al., 
1997, Hilgendorf, et al., 2007, Jung, et 
al., 2008, Nies, et al., 2008, Nies, et al., 
2009, Nishimura and Naito, 2005, 
Tzvetkov, et al., 2009, Zhang, et al., 
1997b, Zhang, et al., 2000 
Heart 
+  
Jung, et al., 2008, Nishimura and Naito, 
2005, Zhang, et al., 1997b 
Skeletal muscle 
+  
Gorboulev, et al., 1997, Jung, et al., 
2008, Nishimura and Naito, 2005, 
Zhang, et al., 1997b 
Kidney + + 
Dickens, et al., 2012, Gorboulev, et al., 
1997, Hilgendorf, et al., 2007, Nies, et 
al., 2008, Nies, et al., 2009, Nishimura 
and Naito, 2005, Pietig, et al., 2001, 
Tzvetkov, et al., 2009, Zhang, et al., 
1997b 
Lung + + 
Jung, et al., 2008, Lips, et al., 2005, 
More, et al., 2010, Nies, et al., 2009, 
Nishimura and Naito, 2005 
Small intestine + + 
Gorboulev, et al., 1997, Hilgendorf, et 
al., 2007, Jung, et al., 2008, Muller, et 
al., 2005, Nishimura and Naito, 2005, 
Tzvetkov, et al., 2009, Zhang, et al., 
2000 
Large intestine +  
Gorboulev, et al., 1997, Hilgendorf, et 
al., 2007, Jung, et al., 2008, Nishimura 
and Naito, 2005 
Stomach +  
Gorboulev, et al., 1997, Nishimura and 
Naito, 2005 
Prostate +  
Jung, et al., 2008, Nishimura and Naito, 
2005 
Ovary +  Jung, et al., 2008 




Placenta +  
Gorboulev, et al., 1997, Nishimura and 
Naito, 2005 
Mammary gland +  Jung, et al., 2008 
Adrenal gland +  
Nies, et al., 2009, Nishimura and Naito, 
2005 
Salivary gland +  Nishimura and Naito, 2005 
Thyroid +  Nishimura and Naito, 2005 
Pancreas +  
Jung, et al., 2008, Nies, et al., 2009, 
Nishimura and Naito, 2005 
Thymus +  Nishimura and Naito, 2005 
Spleen +  
Gorboulev, et al., 1997, Jung, et al., 
2008, Nies, et al., 2009, Nishimura and 
Naito, 2005 
Testis +  
Jung, et al., 2008, Nies, et al., 2009, 
Nishimura and Naito, 2005 
Brain + + 
Dickens, et al., 2012, Gorboulev, et al., 
1997, Lin, et al., 2010, More, et al., 2010 
Adipose +  Moreno-Navarrete, et al., 2011 
Bone marrow +  Nishimura and Naito, 2005 
Aberrant 
Expression 
CML (leukocytes) +  Thomas, et al., 2004 
CLL (lymphocytes) +  Gupta, et al., 2012 






1.3.3.1 Regulation of hOCT1 Expression 
The robust expression of hOCT1 in the liver suggests the existence of a 
hepatocyte-specific expression regulation system. Saborowski, et al., (2006) identified 
putative hepatocyte nuclear factor 4α (HNF4α) response elements within the hOCT1 
gene promoter. Indeed, they were able to demonstrate that HNF4α regulates hOCT1 
gene expression. Additionally, they determined that bile acids can suppress hOCT1 
gene activation via the nuclear receptor FXR which induces the transcriptional repressor 
SHP, effectively repressing HNF4α transactivation of the hOCT1 promoter (Saborowski, 
et al., 2006). This finding may explain the decreased levels of hepatic hOCT1 
expression observed in cholestasis patients (Nies, et al., 2009).  
High levels of hepatic expression in hOCT1 may also be attributed to hepatocyte 
nuclear factor 1 (HNF1). Bioinformatics analyses identified strong HNF1 binding motifs 
within the evolutionary conserved region in intron 1 of the hOCT1 gene (O'Brien, et al., 
2013). Follow-up studies confirmed HNF1 binding to the identified sequence in intron 1, 
and demonstrated a robust upregulation of hOCT1 expression when overexpressed in 
hepatocyte-derived cell lines (O'Brien, et al., 2013). Furthermore, high HNF1 expression 
levels significantly correlated with high hOCT1 expression in human liver samples, 
suggesting that HNF1 and HNF4α may work in parallel to regulate hepatic expression of 
hOCT1. 
In addition to regulation by hepatocyte nuclear factors, hOCT1 expression 
appears to be controlled by several xenobiotic-sensing nuclear receptors. Jigorel, et al., 




to induce drug-metabolizing enzymes, on expression of several hepatic drug 
transporters in isolated human hepatocytes. When hepatocytes were treated with 
TCDD, an activator of the aryl hydrocarbon receptor (AhR), phenobarbital, activator of 
the constitutive androstane receptor (CAR), and rifampicin, activator of the pregnane X 
receptor (PXR), hOCT1 mRNA expression decreased. Their findings suggest that, when 
activated, AhR, CAR, and PXR all downregulate hOCT1 expression, either individually 
or in concert. Further studies substantiated the role of PXR in downregulation of hOCT1 
expression. Hyrsova, et al., (2016) verified a decrease in hOCT1 expression at the 
mRNA and protein levels in primary human hepatocytes, and demonstrated diminished 
hOCT1-mediated transport, confirming a reduction in functional hOCT1 protein levels 
following activation of PXR. They determined that the mechanism of PXR-mediated 
suppression of hOCT1 involves the transcriptional coactivator SRC-1. Their results 
suggest that SRC-1 is a required coactivator for HNF4α, and PXR competes for, or 
“squelches” SRC-1, thereby inhibiting HNF4α-mediated hOCT1 expression (Hyrsova, et 
al., 2016). 
The findings by Jigorel, et al., (2006) and Hyrsova, et al., (2016) that PXR 
downregulates hOCT1 expression are contrary to conclusions drawn by other groups. 
Cho, et al., (2011) reported an observed increase in the glucose-lowering effect of 
metformin, a hOCT1 substrate, when given to patients after treatment with PXR 
activator, rifampicin. They followed up this observation by determining hOCT1 mRNA 
levels in peripheral blood cells with and without rifampicin treatment. Their results 
demonstrated an increase in hOCT1 mRNA in peripheral blood cells following rifampicin 




liver, thus explaining the observed changes in glucose-lowering effect of metformin, 
though this hypothesis was not tested. Furthermore, freshly isolated human blood 
mononuclear cells from CML patients exhibit increased hOCT1 expression following 
treatment with rifampicin (Austin, et al., 2015). Combined, these data indicate that PXR 
upregulates hOCT1 expression, though it’s important to note that these observations 
were made from studies using blood cells, not hepatocytes, which may explain the 
discrepancies with other reports in regards to the role of PXR in regulation of hOCT1 
expression, and suggests the possibility of tissue-specific regulation. 
1.3.3.2 hOCT1 Functional Regulation 
Post-translational modifications, particularly phosphorylation, appear to be 
significant in modulating hOCT1 function. Multiple groups have reported that hOCT1 
has predicted phosphorylation sites for protein kinases A, C, and G (highlighted in 
Figure 1.2; Ciarimboli and Schlatter, 2005, Gorboulev, et al., 1997). In vitro studies in 
transfected Chinese hamster ovary (CHO) and human embryonic kidney (HEK) cells 
demonstrated that hOCT1 transport is inhibited when protein kinase A (PKA) is 
activated (Ciarimboli, et al., 2004). Interestingly, it was found that PKC activation 
stimulates uptake by rOCT1 (Mehrens, et al., 2000), but appears to exert no effect on 
hOCT1 (Ciarimboli, et al., 2004). To date, there have been no reports regarding 
modulation of hOCT1 by PKG. 
It appears that phosphorylation by additional kinases may be important in hOCT1 
functional regulation. For example, published data suggest that Src family tyrosine 




kinase inhibitors (TKIs) that deactivate Src family tyrosine kinases noncompetitively and 
reversibly inhibit OCT2 function. They also determined that tyrosine phosphorylation is 
critical for OCT2 function, and proposed this same mechanism of regulation for all 
organic cation transporters. Indeed, this may be the case for hOCT1, as Ciarimboli, et 
al. (2004) revealed that the Src-like tyrosine kinase p56lck appears to regulate hOCT1 
activity.  
Endogenous calcium signaling pathways also appear to functionally regulate 
hOCT1. It was reported that hOCT1 activity is endogenously stimulated by calmodulin 
(CaM) and calmodulin-dependent kinase II (CaMKII), evidenced by an observed 
decrease in hOCT1 activity when both enzymes were pharmacologically inhibited by 
CaM inhibitor calmidazolium (Ciarimboli, et al., 2004). 
1.3.4 hOCT1 Structure 
hOCT1 is a large, 554 amino acid, transmembrane glycoprotein, with a predicted 
molecular weight of approximately 61 kD, based on its amino acid sequence. 
Hydropathy analysis suggests that the protein contains twelve α-helical transmembrane 
(TM) domains, a common trait among all members of the SLC22 family, with 
cytoplasmic amino- and carboxy-termini (Gorboulev, et al., 1997, Zhang, et al., 1997b). 
The predicted membrane topology also includes a large extracellular loop (ECL), 
comprised of 110 amino acids located between the first and second TM domains, as 
well as a smaller, 66 amino acid cytoplasmic loop (CL) between the sixth and seventh 




residues 71, 96, and 112 (indicated by black stars in Figure 1.2), two of which are 
conserved within the OCT family (Gorboulev, et al., 1997, Zhang, et al., 1997b).  
Data suggests that the ECL is essential for expression of functional transporters. 
When the six ECL cysteine residues of rOCT1 were individually mutated to serine, no 
discernable transport of TEA was observed (Sturm, et al., 2007). The authors of this 
study speculate that the sulfhydryl groups in these six conserved cysteines form 
disulfide bonds that are critical for stabilization of tertiary structure of the ECL. 
Combining results from their own studies with information published regarding the effect 
of glycosylation on proper folding of the ECL in rabbit OCT2 (Pelis, et al., 2006), Sturm, 
et al. conclude that proper ECL tertiary structure is essential for OCT insertion into the 
membrane. This was later confirmed for rOCT1 (Keller, et al., 2011) and hOCT1 
(Arimany-Nardi, et al., 2016). 
The ECL is also implicated in OCT oligomerization. Keller, et al. (2008) 
synthesized His- and FLAG-tagged rOCT1 by a cell-free expression system. After 
affinity purification over a nickel column, which binds His-tag, FLAG-tagged rOCT1 
constructs could be detected by Western blot, suggesting rOCT1 oligomerizes. When 
the cysteine residues within the ECL were mutated or the amino acid sequence of the 
ECL was replaced with that of the ECL from rOAT1, oligomerization was significantly 
reduced (Keller, et al., 2011), suggesting that the ECL is pivotal for OCT 
oligomerization.  
To date, a crystal structure has not been determined for any SLC22 family 





Figure 1.2. Amino acid sequence and predicted membrane topology of hOCT1. The 
predicted structure of human OCT1 includes twelve putative transmembrane domains 
(blue cylinders), a large extracellular loop (ECL), a smaller cytoplasmic loop (CL), and 
intracellular amino- and carboxy-termini. Potential N-glycosylation sites are designated by 
an asterisk ( * ). Predicted phosphorylation sites are notated by a dot ( • ) for PKA, a 
square ( ■ ) for PKC, and a triangle ( ▲ ) for PKG (Ciarimboli and Schlatter, 2005). Amino 
acid arrangement in this figure adapted from sequence, hydropathy, and topology 




TM domains. The lack of crystal structures can make structural analysis of transporters 
difficult. Computational modeling is a tool that can be useful in overcoming this obstacle. 
Indeed, homology modeling is a useful tool for identifying potential substrate binding 
sites and relating functional data to transporter structure. A rOCT1 homology model, 
which modeled the TM domains of rOCT1 based on the crystal structure of bacterial 
major facilitator superfamily member lactose LacY (Abramson, et al., 2003), was 
published in 2005 (Popp, et al., 2005). Using this homology model, the authors related 
rOCT1 mutagenesis data to structural components and elucidated a putative binding 
pocket. Comparative modeling of hOCT1 substrate binding regions to the crystal 
structure of fungal transporter PiPT (Pedersen, et al., 2013) is also useful in the 
prediction of competitive and noncompetitive ligands (Chen, et al., 2017), though it is 
important to note that subsequent in vitro and in vivo studies are necessary to validate 
findings derived from computational models. 
Very few structural analyses have been performed using hOCT1. While the 
majority of structural information available for OCT1 homologs is derived from the above 
reports utilizing rOCT1 constructs, it is likely that these data are relatable to hOCT1, 
with some important caveats, due to primarily differences in substrate specificity and 
affinity, because of the high similarity in secondary structure and conserved regions 
(Gorboulev, et al., 1997, Zhang, et al., 1997b). 
1.3.5 Mechanisms of Transport for hOCT1 
SLC family transporters are facilitated diffusion systems which do not require the 




vastly varied. hOCT1, like other OCTs, is an electrogenic transporter, meaning electric 
current (measured by electrophysiology techniques) can be detected during substrate 
transport (Dresser, et al., 2000). This is likely due to the charged nature of substrates. 
The driving force of transport appears to be a combination of the substrate 
concentration gradient and membrane potential, as hOCT1 functions independently of 
sodium, chloride, and pH (Koepsell, 2004, Zhang, et al., 1997b). 
Another common property of OCT transport is the ability to translocate substrates 
across the cell membrane bi-directionally; thus, OCTs effectively function as both influx 
and efflux transporters (Koepsell, et al., 2003). Indeed, several groups have confirmed 
that OCT1 (human and rat) can transport substrates in both directions, sometimes 
seemingly exchanging an intracellular substrate for a different substrate outside the cell 
(Arimany-Nardi, et al., 2014, Lips, et al., 2005, Zhang, et al., 1998). 
OCTs transport a wide array of structurally dissimilar cationic and uncharged 
organic molecules (see a summary of hOCT1 substrates in Tables 1.2-1.4). The ability 
to translocate such diverse chemical structures is a property common to many of the 
SLC22 family members. The mechanism behind this is not well understood and is the 
subject of a great deal of research. Several mutagenesis studies have identified certain 
amino acids within putative OCT binding sites that alter the transport of one substrate, 
but not others (Gorboulev, et al., 1999, Gorboulev, et al., 2005, Popp, et al., 2005, 
Zhang, et al., 2005). Additional reports describe substrate-dependent ligand interactions 
for OCTs and other SLC22 family transporters (see section 1.5 for further discussion; 
Belzer, et al., 2013, Harper and Wright, 2013, Martínez-Guerrero and Wright, 2013). 




substrate and inhibitor binding pockets or one large binding region, wherein specific 
binding sites may overlap (Chen, et al., 2017, Ciarimboli, et al., 2004, Ciarimboli and 
Schlatter, 2005, Koepsell, et al., 2003). This may explain how hOCT1 facilitates the 
binding and translocation of such structurally diverse substrates with varying degrees of 
affinity. 
It is also important to consider the consequences of microenvironment on 
transporter function. In view of the fact that substrate affinity can be different for multiple 
substrates depending on the overexpression system employed (Nies, et al., 2011b), it is 
quite possible that the lipid composition and protein content of the plasma membrane 
may influence transporter function (Umehara, et al., 2007). 
 
1.3.6 hOCT1 Substrate and Inhibitor Specificity 
As discussed above, hOCT1 interacts with a wide array of structurally diverse 
molecules. These include numerous drugs from various drug classes and other 
xenobiotics, as well as endogenous compounds. A summary of hOCT1 substrates and 
inhibitors can be found in Tables 1.2-1.5.  
Multiple groups have analyzed the physicochemical properties of hOCT1 ligands 
(Ahlin, et al., 2008, Bednarczyk, et al., 2003, Chen, et al., 2017, Liu, et al., 2016, 
Moaddel, et al., 2007). In general, the molecular weight of hOCT1 ligands is less than 
500 Daltons. Ligands tend to be fairly hydrophobic and, as the transporter name would 




Table 1.2. Select drug substrates of hOCT1. 
Substrate Drug Classification Reference 
Disopyramide Antiarrhythmic Hendrickx, et al., 2013 
Procainamide Antiarrhythmic Hendrickx, et al., 2013 
Quinidine Antiarrhythmic van Montfoort, et al., 2001 
Norfloxacin Antibiotic Ciarimboli, et al., 2013 
Ofloxacin Antibiotic Ciarimboli, et al., 2013 
Trimethoprim Antibiotic Hendrickx, et al., 2013, Jung, et al., 2008 
Atropine Anticholinergic Hendrickx, et al., 2013 
Clidinium Anticholinergic Hendrickx, et al., 2013 




Hendrickx, et al., 2013 
Mepenzolate Anticholinergic Hendrickx, et al., 2013 




Hendrickx, et al., 2013 
Lamotrigine Anticonvulsant Dickens, et al., 2012 
Metformin Antidiabetic Ahlin, et al., 2011, Kimura, et al., 2005 
Phenformin Antidiabetic Hendrickx, et al., 2013 
Metoclopramide Antiemetic/prokinetic Hendrickx, et al., 2013 
Tropisetron Antiemetic Tzvetkov, et al., 2012 
Atenolol Antihypertensive 
Ciarimboli, et al., 2013, Hendrickx, et al., 
2013 








Briz, et al., 2002 
Bendamustine Antineoplastic Arimany-Nardi, et al., 2015 
Carboplatin Antineoplastic Zhang, et al., 2006 
CDPCP Antineoplastic Li, et al., 2011 
Cisplatin Antineoplastic 
Yonezawa, et al., 2006, Zhang, et al., 
2006 
Daunorubicin Antineoplastic Andreev, et al., 2016 
Imatiniba 
Antineoplastic/ 
tyrosine kinase inhibitor 
Burger, et al., 2013, Hu, et al., 2008, Nies, 
et al., 2014, Thomas, et al., 2004, Wang, 




Irinotecan Antineoplastic Gupta, et al., 2012 
Oxaliplatin Antineoplastic 
Li, et al., 2011, Minematsu and Giacomini, 
2011, Yonezawa, et al., 2006, Zhang, et 
al., 2006 
Paclitaxel Antineoplastic Gupta, et al., 2012 
Picoplatin Antineoplastic More, et al., 2010 
Sorafenib 
Antineoplastic/ 
tyrosine kinase inhibitor 




Minematsu, et al., 2010 
Zebularine Antineoplastic Arimany-Nardi, et al., 2014 
Furamidine Antiparasitic Ming, et al., 2009 
Pentamidine Antiparasitic Jung, et al., 2008, Ming, et al., 2009 
Amisulpride Antipsychotic Dos Santos Pereira, et al., 2014 
Sulpiride Antipsychotic Dos Santos Pereira, et al., 2014 
Perphenazine Antipsychotic Hendrickx, et al., 2013 
Acyclovir Antiviral Takeda, et al., 2002 
Efavirenz Antiviral Moss, et al., 2015 
Ganciclovir Antiviral Takeda, et al., 2002 
Lamivudine Antiviral Jung, et al., 2008, Minuesa, et al., 2009 





























Kimura, et al., 2009 
Amiloride Diuretic Hendrickx, et al., 2013 
Triamterene Diuretic Hendrickx, et al., 2013 
Cimetidine H2-antagonist Hendrickx, et al., 2013 






 Status of imatinib as a substrate is controversial. See references.  
Nizatidine H2-antagonist Hendrickx, et al., 2013 
Ranitidine H2-antagonist 
Bourdet, et al., 2005, Hendrickx, et al., 
2013 
Varenicline 
Nicotinic receptor partial 
agonist/ smoking 
cessation aid 
Hendrickx, et al., 2013 
Morphine Opioid Tzvetkov, et al., 2013 
O-desmethyltramadol Opioid metabolite Tzvetkov, et al., 2011 
mIBG Radiopharmaceutical Bayer, et al., 2009 
Sumatriptan Serotonin receptor agonist Hendrickx, et al., 2013 
Eltrombopag 
Thrombopoietin  receptor 
agonist 




Table 1.3. Other xenobiotic and model substrates of hOCT1. 
Substrate Classification Reference 
Quercetin Flavanoid Glaeser, et al., 2014 
DAPI Fluorescent dye Yasujima, et al., 2011 




Lee, et al., 2009 
Paraquat Herbicide Chen, et al., 2007 
APDA Model cation van Montfoort, et al., 2001 




Ahlin, et al., 2008 
Azidoprocainamide Model cation van Montfoort, et al., 2001 
MPP+ Model cation 
Gorboulev, et al., 1997, Grundemann, et 
al., 2003, Umehara, et al., 2007, Zhang, et 
al., 1997b 
N-methylquinidine Model cation van Montfoort, et al., 2001 
N-methylquinine Model cation van Montfoort, et al., 2001 
TBA Model cation Dresser, et al., 2000 
TBuMA Model cation van Montfoort, et al., 2001 
TEA Model cation 
Bednarczyk, et al., 2003, Gorboulev, et 
al., 1997, Umehara, et al., 2007, Zhang, et 
al., 1998 
TMA Model cation Dresser, et al., 2000 
TPrA Model cation Dresser, et al., 2000 
Aflatoxin B1 Mycotoxin Tachampa, et al., 2008 
MPTP 
Neurotoxin 
(prodrug of MPP+) 
Lin, et al., 2010 
Berberine Plant alkaloid Nies, et al., 2008 
Berberrubine Plant alkaloid Li, et al., 2016 
Coptisine Plant alkaloid Li, et al., 2016 
Epiberberine Plant alkaloid Li, et al., 2016 
Jatrorhizine Plant alkaloid Li, et al., 2016 
Monocrotaline Plant alkaloid Tu, et al., 2013 
Nitidine Plant alkaloid Li, et al., 2014b 





Table 1.4. Endogenous substrates of hOCT1. 
Substrate Classification Reference 
Prostaglandin E2a Eicosanoid Harlfinger, et al., 2005, Kimura, et al., 2002 
Prostaglandin F2a Eicosanoid Harlfinger, et al., 2005, Kimura, et al., 2002 
Agmatine Metabolite 
Grundemann, et al., 2003, Winter, et al., 
2011 
N-methylnicotinamide Metabolite Gorboulev, et al., 1997 
Putrescine Metabolite Winter, et al., 2011 
Spermidine Metabolite Sala-Rabanal, et al., 2013 
Acetylcholine Neurotransmitter Lips, et al., 2005 
Dopamine Neurotransmitter Bayer, et al., 2009, Boxberger, et al., 2014 
Norepinephrine Neurotransmitter Bayer, et al., 2009, Boxberger, et al., 2014 
Serotonin Neurotransmitter Boxberger, et al., 2014, Kerb, et al., 2002 
Thiamine Vitamin Chen, et al., 2014 
 
a





Table 1.5. Select inhibitors of hOCT1. 




Chen, et al., 2017 
Acetaminophen Analgesic Khamdang, et al., 2002 
Phenacetin Analgesic Khamdang, et al., 2002 
Salicylamide Analgesic Yasujima, et al., 2011 
Flecainide Antiarrhythmic Umehara, et al., 2008 
Lidocaine Antiarrhythmic/anesthetic Yasujima, et al., 2011 
Propafenone Antiarrhythmic Ahlin, et al., 2008 
Chloramphenicol Antibiotic Yasujima, et al., 2011 
Ciprofloxacin Antibiotic Mulgaonkar, et al., 2013 
Ethambutol Antibiotic Pan, et al., 2013 
Fleroxacin Antibiotic Mulgaonkar, et al., 2013 
Gatifloxacin Antibiotic Mulgaonkar, et al., 2013 
Levofloxacin Antibiotic Mulgaonkar, et al., 2013 
Lomefloxacin Antibiotic Mulgaonkar, et al., 2013 
Moxifloxacin Antibiotic Mulgaonkar, et al., 2013 
Perfloxacin Antibiotic Mulgaonkar, et al., 2013 
Prulifloxacin Antibiotic Mulgaonkar, et al., 2013 
Rufloxacin Antibiotic Mulgaonkar, et al., 2013 
Sparfloxacin Antibiotic Mulgaonkar, et al., 2013 
Butylscopalomine Anticholinergic Muller, et al., 2005 
Camylofine Anticholinergic Chen, et al., 2017 
Orphenadrine Anticholinergic Ahlin, et al., 2008 
Oxybutynin Anticholinergic Ahlin, et al., 2008 
Pancuronium Anticholinergic Zhang, et al., 1997b 
Propantheline Anticholinergic Yasujima, et al., 2011 
Tubocurarine Anticholinergic Minematsu, et al., 2010 
Rocuronium Anticholinergic van Montfoort, et al., 2001 




Ahlin, et al., 2008 
Clopidogrel Anticoagulant Li, et al., 2014a 
Carbamazepine Anticonvulsant Yasujima, et al., 2011 
Phenobarbital Anticonvulsant Yasujima, et al., 2011 
Phenytoin Anticonvulsant Yasujima, et al., 2011 
Primidone Anticonvulsant Yasujima, et al., 2011 




Bupropion Antidepressant Haenisch, et al., 2012 
Citalopram Antidepressant Ahlin, et al., 2008 
Clomipramine Antidepressant  Ahlin, et al., 2008 
Desipramine Antidepressant Ahlin, et al., 2008, Zhang, et al., 1998 
Doxepin Antidepressant Haenisch, et al., 2012 
Fluoxetine Antidepressant Haenisch, et al., 2012 
Fluvoxamine Antidepressant Haenisch, et al., 2012 
Imipramine Antidepressant Ahlin, et al., 2008 
Maprotiline Antidepressant Haenisch, et al., 2012 
Mianserin Antidepressant Haenisch, et al., 2012 
Mirtazapine Antidepressant Haenisch, et al., 2012 




Haenisch, et al., 2012 
Nomifensine Antidepressant Haenisch, et al., 2012 
Paroxetine Antidepressant Haenisch, et al., 2012 
Reboxetine Antidepressant Haenisch, et al., 2012 
Sertraline Antidepressant Haenisch, et al., 2012 
Tianeptine Antidepressant Haenisch, et al., 2012 
Trimipramine Antidepressant Ahlin, et al., 2008 
Venlafaxine Antidepressant Haenisch, et al., 2012 
Glyburide Antidiabetic Yasujima, et al., 2011 
Repaglinide Antidiabetic 
Ahlin, et al., 2008, Bachmakov, et al., 
2008 
Rosiglitazone Antidiabetic Bachmakov, et al., 2008 
Sitagliptin Antidiabetic Choi, et al., 2010 
Ondansetron Antiemetic Ahlin, et al., 2008, Tzvetkov, et al., 2012 
Clotrimazole Antifungal Ahlin, et al., 2008 
Fluconazole Antifungal Yasujima, et al., 2011 




Ahlin, et al., 2008 
Diphenhydramine Antihistamine Lee, et al, 2009, Muller, et al., 2005 




Ahlin, et al., 2008 
Terfenadine Antihistamine Ahlin, et al., 2008 








Ahlin, et al., 2008 
Carvedilol Antihypertensive Chen, et al., 2017 
Clonidine Antihypertensive 
Ahlin, et al., 2008, Bednarczyk, et al., 
2003, Zhang, et al., 1997b 
Diltiazem 
Antihypertensive/ 
calcium channel blocker 
Ahlin, et al., 2008, Umehara, et al., 2008 
Guanabenz Antihypertensive Chen, et al., 2017 
Methoxyverapamil 
Antihypertensive/ 
calcium channel blocker 
Ahlin, et al., 2008 
Metoprolol Antihypertensive Umehara, et al., 2008 
Nitroprusside Antihypertensive Chen, et al., 2017 
Oxprenolol Antihypertensive Ahlin, et al., 2008 
Phenoxybenzamine Antihypertensive 
Ahlin, et al., 2008, Hayer-Zillgen, et al., 
2002 
Prazosin Antihypertensive 
Ahlin, et al., 2008, Hayer-Zillgen, et al., 
2002 
Propranolol Antihypertensive Ahlin, et al., 2008 
Terazosin Antihypertensive Ahlin, et al., 2008 
Verapamil 
Antihypertensive/ 
calcium channel blocker 
Ahlin, et al., 2008, Zhang, et al., 1997b 
Cochicine Anti-inflammatory Yasujima, et al., 2011 
Sulfasalazine Anti-inflammatory Yasujima, et al., 2011 
Pyrimethamine Antimalarial Chen, et al., 2017 
Quinine Antimalarial Ahlin, et al., 2008, Zhang, et al., 1997b 
Afatinib Antineoplastic Johnston, et al., 2014 
Amsacrine Antineoplastic Ahlin, et al., 2008 
Bosutinib Antineoplastic Johnston, et al., 2014 
Cediranib Antineoplastic Johnston, et al., 2014 
Cepharanthine Antineoplastic Moss, et al., 2015 
Dasatinib Antineoplastic Minematsu and Giacomini, 2011 
Erlotinib Antineoplastic Minematsu and Giacomini, 2011 
Etoposide Antineoplastic Gupta, et al., 2012 
Foretinib Antineoplastic Johnston, et al., 2014 
Gefitinib Antineoplastic Minematsu and Giacomini, 2011 
Ifosfamide Antineoplastic Gupta, et al., 2012 
Lapatinib Antineoplastic Minematsu and Giacomini, 2011 
Mitaxantrone Antineoplastic Gupta, et al., 2012 




Nilotinib Antineoplastic Minematsu and Giacomini, 2011 
Pelitinib Antineoplastic Johnston, et al., 2014 
Sorafenib Antineoplastic Minematsu and Giacomini, 2011 
Sunitinib Antineoplastic Minematsu and Giacomini, 2011 
Tamoxifen Antineoplastic Ahlin, et al., 2008 
Vandetanib Antineoplastic Johnston, et al., 2014 
Vinblastine Antineoplastic Moaddel, et al., 2005b 
Bithionol Antiparasitic Chen, et al., 2017 
Closantel Antiparasitic Chen, et al., 2017 
Dichlorophen Antiparasitic Chen, et al., 2017 
Chlorpromazine Antipsychotic 
Ahlin, et al., 2008, Bednarczyk, et al., 
2003 
Chlorprothixene Antipsychotic Ahlin, et al., 2008 
Clozapine Antipsychotic Haenisch, et al., 2012 
 Flupentixol Antipsychotic Ahlin, et al., 2008 
Fluphenazine Antipsychotic Ahlin, et al., 2008 
Haloperidol Antipsychotic Ahlin, et al., 2008 
Levomepromazine Antipsychotic Haenisch, et al., 2012 
Olanzapine Antipsychotic Haenisch, et al., 2012 
Perazine Antipsychotic Haenisch, et al., 2012 
Prochlorperazine Antipsychotic Ahlin, et al., 2008 
Promazine Antipsychotic Ahlin, et al., 2008 
Quetiapine Antipsychotic 
Dickens, et al., 2012, Haenisch, et al., 
2012 
Remoxipride Antipsychotic Haenisch, et al., 2012 
Risperidone Antipsychotic Haenisch, et al., 2012 
Sertindole Antipsychotic Haenisch, et al., 2012 
Spiperone Antipsychotic Haenisch, et al., 2012 
Thioridazine Antipsychotic Haenisch, et al., 2012 
Zotepine Antipsychotic Haenisch, et al., 2012 
Zuclopenthixol Antipsychotic Haenisch, et al., 2012 
Carbapentane Antitussive Chen, et al., 2017 
Cloperastine Antitussive Chen, et al., 2017 
Dextromethorphan Antitussive Chen, et al., 2017 
Abacavir Antiviral Minuesa, et al., 2009 
Amprenavir Antiviral Moss, et al., 2015 
Azidothymidine Antiviral Minuesa, et al., 2009 
Darunavir Antiviral Moss, et al., 2015 




Etravirine Antiviral Moss, et al., 2015 
Indinavir Antiviral Jung, et al., 2008, Zhang, et al., 2000 
Lopinavir Antiviral Moss, et al., 2015 
Nelfinavir Antiviral Jung, et al., 2008, Zhang, et al., 2000 
Nevirapine Antiviral Moss, et al., 2015 
Rilpivierine Antiviral Moss, et al., 2015 
Ritonavir Antiviral Jung, et al., 2008, Zhang, et al., 2000 
Saquinavir Antiviral Jung, et al., 2008, Zhang, et al., 2000 
Stavudine Antiviral Moss, et al., 2015 
Tenofovir Antiviral Minuesa, et al., 2009 
Denopamine β1-agonist Ahlin, et al., 2008 
Dobutamine β1-agonist Chen, et al., 2017 




Salomon, et al., 2015 
Isoproterenol β-agonist (non-selective) Moaddel, et al., 2007 
Midazolam Benzodiazepine Zhang, et al., 1998 
Taurocholate Bile acid Zhang, et al., 1997b 
Histamine Biogenic amine Bednarczyk, et al., 2003 
Ouabain Cardiac glycoside Yasujima, et al., 2011 




Yasujima, et al., 2011 




Ahlin, et al., 2008 
Bromosulfophthalein Dye Yasujima, et al., 2011 
Crystal violet Dye Bednarczyk, et al., 2003 
EGCG Flavonoid Knop, et al., 2015 
Kaempferol Flavonoid Yasujima, et al., 2011 
Naringenin Flavonoid Yasujima, et al., 2011 
Phlorizin Flavonoid Yasujima, et al., 2011 
Rutin Flavonoid Yasujima, et al., 2011 
Azathioprine Immunosuppressant Yasujima, et al., 2011 
Creatinine Metabolite Zhang, et al., 1998 
Guanidine Metabolite Zhang, et al., 1997b 
Guanidinosuccinic 
acid 
Metabolite Kimura, et al., 2009 




Methylguanidine Metabolite Kimura, et al., 2009 
Tyramine Metabolite Bednarczyk, et al., 2003 
Cyclohexylamine Model cation Bednarczyk, et al., 2003 
Decynium-22 Model cation 
Hayer-Zillgen, et al., 2002, Zhang, et al., 
1997b 
THA Model cation Zhang, et al., 1999 
TPeA Model cation 
Bednarczyk, et al., 2003, Zhang, et al., 
1998 
Citreoviridin Mycotoxin Tachampa, et al., 2008 
Gliotoxin Mycotoxin Tachampa, et al., 2008 
Rubratoxin B Mycotoxin Tachampa, et al., 2008 
Zearalenone Mycotoxin Tachampa, et al., 2008 
α-Zearalenol Mycotoxin metabolite Tachampa, et al., 2008 
Amantadine 
NMDA receptor antagonist/ 
dopaminergic 
(Parkinson’s therapeutic) 
Amphoux, et al., 2006, Bednarczyk, et al., 
2003, Zhang, et al., 1998 
Dizocilpine NMDA receptor antagonist Amphoux, et al., 2006 
Ethopropazine NMDA receptor antagonist Chen, et al., 2017 
Ketamine 
NMDA receptor antagonist 
(dissociative anesthetic) 
Amphoux, et al., 2006 
Memantine 
NMDA receptor antagonist 
(Alzheimer’s therapeutic) 
Ahlin, et al., 2008 
Phencyclidine 
NMDA receptor antagonist 
(dissociative anesthetic) 
Amphoux, et al., 2006 
Acetylsalicylic acid NSAID Khamdang, et al., 2002 
Diclofenac NSAID Khamdang, et al., 2002 
Ibuprofen NSAID Khamdang, et al., 2002 
Indomethacin NSAID Khamdang, et al., 2002 
Ketoprofen NSAID Khamdang, et al., 2002 
Mefenamic acid NSAID Khamdang, et al., 2002 
Naproxen NSAID Khamdang, et al., 2002 
Piroxicam NSAID Khamdang, et al., 2002 
Sulindac NSAID Khamdang, et al., 2002 
Inosine Nucleoside Zhang, et al., 1997b 
Thymidine Nucleoside Zhang, et al., 1997b 
Uridine Nucleoside Yasujima, et al., 2011 
Nitrobenzylthioinosine Nucleoside analogue Yasujima, et al., 2011 
Fentanyl Opioid Ahlin, et al., 2008 




Loperamide Opioid/antidiarrheal Ahlin, et al., 2008 
Corydaline Plant alkaloid Li, et al., 2016 
Palmatine Plant alkaloid Li, et al., 2016 
Tetrahydropalmitine Plant alkaloid Tu, et al., 2014 
Gugglesterone Phytosteroid Ahlin, et al., 2008 
Lansoprazole Proton pump inhibitor Nies, et al., 2011a 
Omeprazole Proton pump inhibitor Nies, et al., 2011a 
Pantoprazole Proton pump inhibitor Nies, et al., 2011a 
Rabeprazole Proton pump inhibitor Nies, et al., 2011a 
Tenatoprazole Proton pump inhibitor Nies, et al., 2011a 
6-Fluorodopamine Radiopharmaceutical Bayer, et al., 2009 
Androstenedione Steroid Ahlin, et al., 2008 
β-estradiol Steroid 
Ahlin, et al., 2008, Hayer-Zillgen, et al., 
2002 
Beclometasone Steroid Lips, et al., 2005 
Budesonide Steroid Lips, et al., 2005 
Corticosterone Steroid 
Hayer-Zillgen, et al., 2002, Zhang, et al., 
1998 




Ahlin, et al., 2008 
Estrone-3-sulfate Steroid Yasujima, et al., 2011 
Hydrocortisone Steroid Yasujima, et al., 2011 
Nandrolone Steroid Ahlin, et al., 2008 
Prednisolone Steroid Yasujima, et al., 2011 
Progesterone Steroid 





Ahlin, et al., 2008 
Cocaine Stimulant Amphoux, et al., 2006 
Dextroamphetamine Stimulant Amphoux, et al., 2006 
MDMA Stimulant/hallucinogen Amphoux, et al., 2006 
Nicotine Stimulant 
Bednarczyk, et al., 2003, Zhang, et al., 
1998 
Pseudoephedrine Stimulant Moaddel, et al., 2005a 
Papaverine Vasodilator/antispasmodic Ahlin, et al., 2008 
Choline Vitamin Zhang, et al., 1997b 





and inhibitors have been identified. Structures containing bulkier hydrophobic regions 
tend to be better ligands for hOCT1 than planar molecules. Additionally, hOCT1 ligands 
generally have fewer hydrogen-bond donors and are less polar than non-interacting 
structures. 
Perhaps unsurprisingly, ligand structure influences the mechanism of interaction 
with hOCT1. After analyzing hundreds of ligand interactions with hOCT1, both in silico 
and in vitro, it was determined that noncompetitive inhibitors were significantly larger 
and more hydrophobic than competitive ligands (Chen, et al., 2017), suggesting that 
these two groups bind to different sites on the transporter. This corroborates the 
hypothesis discussed in the previous section of multiple binding sites or a large binding 
“pocket” within the transporter. The identification of multiple, high- and low-affinity 
binding sites for various ligands (Gorbunov, et al., 2008, Minuesa, et al., 2009), both 
substrates and inhibitors, further supports this hypothesis. 
1.3.7 Clinical Significance and Polymorphisms of hOCT1 
In 2010, the International Transporter Consortium, a group of transporter experts 
from across academia, government, and industry, published a white paper discussing 
the clinical importance of several drug transporters (International Transporter, et al., 
2010). According to this publication, hOCT1 is included in a group of transporters 
deemed key in drug disposition and response. Several publications have identified 
polymorphisms (summarized in Table 1.6) which affect hOCT1 function, and 
emphasized the clinical implications of hOCT1 transport of several drugs, especially the 




Table 1.6. Select hOCT1 variants and their functional consequences (increased 








14 Ser→Phe ↑/↓ Shu, et al., 2003, Shu, et al., 2007 
61 Arg→Cys 
↓ 
(due to expression) 
Kerb,et al., 2002, Shu, et al., 2003, Shu, et 
al., 2007 
88 Cys→Arg ↓a Kerb, et al., 2002 
97 Glu→Lys ↓ Chen, et al., 2010 
117 Pro→Leu ↓ Chen, et al., 2010 
189 Ser→Leu −/↓ Shu, et al., 2003, Shu, et al., 2007 
206 Arg→Cys 
↓ 
(due to expression) 
Chen, et al., 2010 
220 Gly→Val ↓ Shu, et al., 2003, Shu, et al., 2007 
283 Pro→Leu ↓ Sakata, et al., 2004, Takeuchi, et al., 2003 
287 Arg→Gly ↓ Sakata, et al., 2004, Takeuchi, et al., 2003 
341 Pro→Leu ↓ Shu, et al., 2003, Takeuchi, et al., 2003 
401 Gly→Ser ↓ 
Kerb, et al., 2002, Sakata, et al., 2004, Shu, 
et al., 2003, Shu, et al., 2007 
408 Met→Val − Shu, et al., 2007 
420 Deletion −/↓ 




(due to expression) 
Shu, et al., 2003, Shu, et al., 2007 
  
a
 Surface expression of C88R was not examined, but the observed decrease in function is 
likely due to decreased expression of the transporter due to the location of the mutation 
in the ECL. ECL cysteines have been determined to be critical for proper insertion of 







In 2002, Kerb, et al., (2002) identified 25 single nucleotide polymorphisms 
(SNPs) in hOCT1, five of which resulted in amino acid changes: R61C, C88R, F160L, 
G401S, and M420del. The R61C, C88R, and G401S mutants demonstrated significantly 
decreased transport capacity. Furthermore, C88R and G401S exhibited significant 
changes in substrate specificity. A later study identified these variants and others in an 
ethnically diverse population sample (Leabman, et al., 2003), and subsequent 
characterization of the new variants identified two amino acid substitutions which 
yielded decreased hOCT1 function (G220V and P341L), and one variant, S14P, which 
exhibited increased transport of MPP+ (Shu, et al., 2003). Interestingly, mutants which 
demonstrated no functional change or increased transport of MPP+, including S14F, 
S189L, and M420del, showed significantly decreased uptake of metformin (Shu, et al., 
2007). Furthermore, several reduced function variants led to decreased activation of 
AMPK, a putative target for metformin, after metformin treatment (Chen, et al., 2010, 
Shu, et al., 2007). 
 In addition to biochemical data demonstrating hOCT1 variant roles in metformin 
action, several hOCT1 polymorphisms appear to be clinically relevant. Shu, et al., 
(2008) demonstrated that metformin pharmacokinetics were altered in individuals 
carrying the reduced function hOCT1 alleles R61C, G401S, M420del, and G465R. 
These alleles resulted in higher metformin AUC, higher Cmax, and lower oral volume of 
distribution, all of which are consistent with these variants’ significantly decreased 
metformin transport. Patients expressing these variants also demonstrated a reduced 
glucose-lowering effect following treatment with metformin (Shu, et al., 2008), 




affect metformin efficacy. Furthermore, hOCT1 polymorphisms are associated with 
adverse drug events in metformin users. The M408V (Tarasova, et al., 2012), R61C, 
and M420del (Dujic, et al., 2016) SNPs are all associated with unfavorable 
gastrointestinal side effects of oral metformin therapy. 
An intronic hOCT1 polymorphism is also implicated in metformin action. The 
intronic SNP rs622342 A>C is seen in several ethnically diverse populations, and is 
associated with a decrease in metformin efficacy, as determined by a decrease in 
HbA1c lowering (Becker, et al., 2009, 2010, Du Plessis, et al., 2015, Ohishi, et al., 2014, 
Umamaheswaran, et al., 2015). This polymorphism is also associated with increased 
dosage and lower response rates to the Parkinson’s drug levodopa (Becker, et al., 
2011). Becker, et al. also demonstrated a 1.5-fold increase in mortality ratio after 
starting levodopa in Parkinson’s patients with one or two copies of the minor allele. 
While these studies demonstrated a putative role for this intronic SNP in the efficacy of 
metformin and levodopa, the mechanism(s) are yet unknown. 
 Though hOCT1 is, perhaps, most clinically implicated in metformin disposition 
and efficacy, it is also recognized in the clinical outcomes of certain chemotherapies. 
hOCT1 expression and genetic polymorphisms are associated with imatinib response 
and resistance in chronic myeloid leukemia patients (Bazeos, et al., 2010, Crossman, et 
al., 2005, Giannoudis, et al., 2013, Kim, et al., 2009, Marin, et al., 2010, Wang, et al., 
2008, White, et al., 2007, White, et al., 2010), though this association is somewhat 
controversial (Hu, et al., 2008, Nies, et al., 2014, Zhang, et al., 2009). Furthermore, 




carcinoma and cholangiocarcinoma, due to both altered expression and function, 
leading to chemoresistance (Herraez, et al., 2013). 
The clinical relevance of hOCT1 has been established for various other drugs as 
well. Several groups have shown that the pharmacokinetics of the opioid analgesics 
morphine and tramadol are dependent on hOCT1 genotype (Tzvetkov, et al., 2011, 
Tzvetkov, et al., 2013, Venkatasubramanian, et al., 2014). In addition, plasma drug 
concentrations and efficacy of the antiemetic drugs ondansetron and tropisetron are 
reduced by loss-of-function hOCT1 polymorphisms (Tzvetkov, et al., 2012). With the 
wide array of clinically-relevant drugs that have been established as hOCT1 substrates, 
it is likely that further studies will identify other medications whose pharmacokinetics 
and/or pharmacological response are varied due to hOCT1 polymorphisms. Altered 
drug pharmacokinetics can lead to decreased drug efficacy and potentially increased 
toxicity, and therefore hOCT1 variants are an important consideration in the preclinical 
and clinical realm during drug development.  
 
1.4 TRANSPORTER-MEDIATED ADVERSE DRUG INTERACTIONS 
Polymorphisms aside, adverse drug interactions, like drug-drug interactions 
(DDIs), are another key factor in altered pharmacokinetics and drug response. DDIs 
occur when the ADME properties of a drug are altered because of co-administration of 
another drug.  With the prominent practice of polypharmacy, or the simultaneous use of 
multiple drugs by one patient for one or more conditions, in the US today, DDIs are 




that nearly 40% of the population age 65 and older take five or more medications 
concurrently (Maher, et al., 2014). Furthermore, an estimated 10% of emergency 
department visits are attributed to adverse drug events (ADEs), including DDIs (Maher, 
et al., 2014). The effects of DDIs include lowered drug efficacy, as a result of decreased 
absorption, and perhaps more importantly, increased drug-induced toxicities resulting 
from decreased metabolism or excretion. For these reasons, DDIs are studied 
extensively, particularly in preclinical studies for investigational new drugs (INDs) 
seeking FDA approval. 
There is a growing appreciation for the role of drug transporters in DDIs. Many 
clinically relevant DDIs have been described for drug transporters in both the ABC and 
SLC transporter families, including P-gp, BCRP, OCTs, OATs, and OATPs 
(International Transporter, et al., 2010). As such, the International Transporter 
Consortium has published a series of papers outlining recommendations for regulatory 
agencies regarding transporter-mediated DDIs (Hillgren, et al., 2013, International 
Transporter, et al., 2010). 
1.4.1 hOCT1-Mediated Drug-Drug Interactions 
While the US Food and Drug Administration (FDA) does not currently include 
hOCT1 in their guidelines for preclinical studies (U.S. Food and Drug Administration, 
2017), the European Medicines Agency (EMA) recommends in vitro inhibition studies 
against hOCT1 for investigational drugs in its Guideline on the Investigation of Drug 
Interactions (European Medicines Agency, 2012). To date, multiple hOCT1 mediated-




Perhaps the most relevant DDIs mediated by hOCT1 involve metformin. 
Administration of the calcium channel blocker verapamil, a potent inhibitor of hOCT1, 
reduces patient response to metformin, presumably through reducing hepatic drug 
levels (Cho, et al., 2014). Various in vitro interactions with metformin have been 
identified as well. Metformin uptake has been shown to be strongly inhibited by several 
tyrosine kinase inhibitors (Minematsu and Giacomini, 2011), the antiarrhythmic drug 
quinidine (Umehara, et al., 2008), and other antidiabetic drugs commonly taken in 
combination with metformin, repaglinide, rosiglitazone (Bachmakov, et al., 2008), and 
sitagliptin (Choi, et al., 2010). With metformin being co-administered with other 
antidiabetic agents or drugs used for treating comorbidities, efficacy can be decreased, 
as described above in the verapamil study. In addition, certain toxicities associated with 
metformin action are possible. 
Antiretroviral drugs employed in HAART therapy for HIV patients comprise 
another set of drugs which can lead to hOCT1-mediated DDIs. Studies in vitro have 
identified several antiretrovirals, including abacavir, azidothymidine, indinavir, nelfinavir, 
ritonavir, saquinavir, and zalcitabine, as hOCT1 inhibitors (Jung, et al., 2008, Minuesa, 
et al., 2009, Zhang, et al., 2000). Furthermore, the NRTI lamivudine was identified as a 
hOCT1 substrate, and all of the antiretrovirals tested potently inhibited lamivudine 
transport by hOCT1 (Jung, et al., 2008, Minuesa, et al., 2009). Lamivudine is frequently 
included in HAART regimens in combination with several other antiretrovirals, including 
those listed above. Therefore, combination therapy may lead to a decrease in 




The prevalence of transporter-mediated DDIs is a strong impetus for 
identification of new DDIs through low-cost and high-throughput drug screens. Several 
groups, therefore, have designed in silico and in vitro high-throughput screening (HTS) 
methods to speed the process of identifying putative DDIs mediated by hOCT1 (Ahlin, 
et al., 2008, Chen, et al., 2017). In vitro studies involved high-throughput inhibition 
testing in homologous expression systems employing a probe substrate. In silico 
studies included modeling physicochemical properties and structure-activity 
relationships of known inhibitors (Ahlin, et al., 2008), and generation of a hOCT1 
homology model with subsequent docking of inhibitors and substrates (Chen, et al., 
2017). These screens identified hundreds of new interactions, and even delineated 
competitive versus noncompetitive inhibitors (Chen, et al., 2017). However, care must 
be taken in the conclusions drawn from these studies as both the modeling and HTS 
methods have limitations, as discussed in their respective reports. Further 
characterization of these putative DDIs is necessary. 
 
1.5 SUBSTRATE-DEPENDENT EFFECTS OF DRUG TRANSPORTERS 
The push to elucidate novel DDIs has presented a new challenge for the 
transporter field. As discussed above, many investigators have turned to high-
throughput screening to speed the process of DDI identification. While HTS can be a 
valuable tool in identifying new interactions, there are disadvantages associated with 
these assays. High-throughput screens typically utilize only one probe substrate at a 




are substrate-dependent, meaning, the effects of ligand interactions (i.e. inhibition, 
stimulation) are conditional, subject to the substrate employed. In the realm of DDI 
identification, substrate-dependent modulation may lead to false-negatives, or missed 
interactions, which may have important implications in drug development. 
Substrate-dependent interactions exhibited by drug transporters were first 
described for efflux pumps of the ABC transporter family, including P-gp, BCRP, and 
some MRPs (Bodo, et al., 2003, Giri, et al., 2009, Honda, et al., 2004). Shortly after, 
several OATPs, members of the SLC transporter superfamily, were implicated in 
substrate-dependent interactions as well. Noé, et al., (2007) demonstrated that 
OATP1B1-mediated transport of several statins and taurocholate was strongly inhibited 
by gemfibrozil, while uptake of troglitazone sulfate was not affected. Interestingly, the 
high-affinity component of estrone-3-sulfate (E3S) transport was inhibitable by 
gemfibrozil, but the low-affinity site was not. Similar substrate-dependent modulation 
has been observed for the other liver-specific OATP, 1B3. The antifungal drug, 
clotrimazole, strongly inhibited OATP1B3-mediated uptake of Fluo-3, had no effect on 
E3S transport, and interestingly, stimulated uptake of E17βG (Gui, et al., 2008). 
Conversely, the green tea catechin, EGCG, inhibited Fluo-3 uptake, exerted no effect 
on E17βG, but markedly stimulated E3S transport, while its close relative, ECG, 
inhibited all three substrates to varying degrees (Roth, et al., 2011). These differential 
effects were mirrored by multiple quercetin derivatives when tested against substrates 
E3S, E17βG, and DHEAS (Zhang, et al., 2013). 
Substrate-dependent effects have been described for other SLC drug 




Martínez-Guerrero and Wright (2013) compared the inhibitor potency of three different 
cationic liquids against three separate MATE substrates. For MATE1, IC50 values for 
Bmim and BmPy were significantly higher when TEMA and NBD-MTMA were employed 
as substrates versus those when MPP+ was used. This inhibitor profile was shared with 
MATE2-K as well, though NBD-MTMA was not tested as a substrate (Martínez-
Guerrero and Wright, 2013). Similarly for MATE1 and MATE2-K, inhibitor IC50 values 
were comparable when screened against metformin, thiamine, and MPP+, but up to ten-
fold higher with rhodamine 123 (Lechner, et al., 2016).  
Members of the organic cation transporter subfamily, most commonly hOCT2, 
have exhibited substrate-dependent modulation. Several structurally diverse cationic 
drugs were markedly more potent inhibitors of hOCT2-mediated metformin transport 
than of MPP+ transport (Zolk, et al., 2009). In addition, hOCT2 exhibited widely varied 
IC50 values for multiple drugs when tested against model substrates MPP
+ and NBD-
MTMA (Belzer, et al., 2013). Furthermore, Hacker, et al., (2015) compared the inhibitory 
effect of numerous hOCT2 ligands against probe substrates MPP+, ASP+, and 
metformin. While they identified several paninhibitors, or ligands which inhibited all three 
substrates, they also discerned selective inhibitors which affected transport of only one 
or two substrates. While these data further validate the existence of substrate-
dependent interactions, they also demonstrate that not every ligand exhibits substrate-
dependent effects. 
To date, no direct studies of substrate-dependent effects have been published for 
hOCT1. However, myriad reports in the literature have established comparatively 




by Nies, et al., (2011b). Due to deviations in transport assays developed by different 
groups, results can’t be directly compared between researchers; thus, there is a need 
for identification and characterization of putative substrate-dependent effects for 
hOCT1. 
 
1.6 SPECIFIC AIMS OF THIS DISSERTATION 
Adverse drug interactions are an increasingly common consequence of the 
practice of polypharmacy in treating comorbidities. There is growing appreciation for the 
role of drug transporters in drug-drug interactions (DDIs). Drug transporters are 
expressed in organs key in drug disposition and are known to interact with a wide 
variety of structurally dissimilar compounds (International Transporter, et al., 2010). Due 
to these inherent characteristics, DDIs frequently occur at the transporter level, and as 
such, regulatory guidelines include recommendations for screening investigational new 
drugs for transporter-mediated DDIs (European Medicines Agency, 2012, U.S. Food 
and Drug Administration, 2017). 
The human organic cation transporter 1 (hOCT1) mediates the uptake of several 
cationic and uncharged drugs, including the antidiabetic agent metformin. Indeed, 
hOCT1 is critical in metformin pharmacokinetics and efficacy. Furthermore, several 
hOCT1-mediated DDIs are implicated in a loss of metformin action and increase in 
certain metformin-associated adverse drug reactions. 
There is currently limited structural information available for hOCT1, therefore, 




Without a comprehensive understanding of these mechanisms, it will remain 
challenging to accurately predict hOCT1-mediated DDIs. Prediction of DDIs is a critical 
first step in their prevention. Therefore, the long term goal of the studies presented in 
this dissertation is to improve methods for accurate prediction of DDIs. The objective of 
this dissertation was to address the lack of understanding, on multiple levels, of the 
mechanisms through which adverse drug interactions occur via hOCT1. 
Several studies have demonstrated that hOCT1 is capable of transporting 
endogenous substrates, though little has been done to characterize the effects of 
endogenous substrate-drug interactions (Kerb, et al., 2002, Kimura, et al., 2002, Lips, et 
al., 2005). In addition, recent studies have suggested that the mechanisms of ligand 
interactions of close relatives of hOCT1 are substrate-dependent (Belzer, et al., 2013, 
Martínez-Guerrero and Wright, 2013), further complicating DDI prediction. The central 
hypothesis of this dissertation is that both endogenous and xenobiotic compounds 
modulate the activity of hOCT1 in a substrate-dependent manner through interaction 
with specific ligand-binding domains within the transporter. Therefore, a multifaceted 
approach was necessary to comprehend the mechanisms of ligand interactions with 
hOCT1. To elucidate structural components key in ligand interactions and determine the 
functional consequences, the following specific aims were employed to test this 
hypothesis:  
1.6.1 Specific Aim 1: Investigate the effect of xenobiotics on endogenous 




Much, if not all of the focus of studies regarding adverse drug interactions of 
hOCT1 are dedicated to DDIs, but little attention has been paid to endogenous 
compound-drug interactions. Monoamine neurotransmitters are substrates for rOCT1, 
but have not been confirmed for hOCT1. In addition, little work has been done to 
characterize inhibitory effects of drugs on monoamine transport. The working 
hypothesis was that hOCT1 mediates the uptake of monoamine neurotransmitters in the 
liver. Furthermore, uptake of these monoamines, which rely on entry into hepatocytes 
for metabolism, can be inhibited by commonly-prescribed drugs. The uptake of 
monoamine neurotransmitters dopamine, norepinephrine, and serotonin by hOCT1 was 
measured. Inhibition of serotonin transport by various drugs was tested and 
characterized in a homologous overexpression system and in primary human 
hepatocytes. 
1.6.2 Specific Aim 2: Identify and characterize substrate-dependent interactions 
with hOCT1 
The working hypothesis of this aim was that the mechanisms of ligand 
interactions with hOCT1 were dependent upon the probe substrate employed. Multiple 
combinations of hOCT1 drug substrates and inhibitors were screened using in vitro 
transporter assays to identify substrate-dependent interactions. The mechanisms of 
these interactions were explored further using in silico docking and structure-activity 
relationship modeling. 
1.6.3 Specific Aim 3: Examine the role of the extracellular loop domain of hOCT1 




The extracellular loop (ECL) domain of OCT1 homologs is critical to substrate 
recognition and binding, and initiation of translocation. While there exists an overlap in 
substrate specificities between rat and human OCT1, significant differences in substrate 
affinities exist between orthologs. The working hypothesis was that the ECL domain is 
important in determining substrate affinity and is the driving force behind the observed 
species differences. To examine this, attempts were made to generate chimeric 
transporters containing the transmembrane domains of hOCT1 but the ECL of rOCT1, 
and vice versa. The goal of this study was to characterize the kinetics of transport for 
several substrates and compare parameters between generated chimeras and wild-type 
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It is widely accepted that the liver plays an essential role in removing drugs, 
toxins and other xenobiotics from circulation in the human body. The liver is also 
involved in the clearance of several endogenous compounds, including circulating 
monoamine neurotransmitters (Chu et al., 1999, Eisenhofer et al., 2004). As early as 
1967, it was demonstrated that the liver is capable of removing more than 70% of the 
serotonin in portal blood by filtration and metabolism (Thomas and Vane, 1967, Tyce, 
1990). Several endogenous compounds, particularly the monoamines, are positively 
charged at physiologic pH, and therefore require transport proteins to facilitate crossing 
the plasma membrane into hepatocytes. However, the high-affinity dopamine (DAT), 
norepinephrine (NET), and serotonin (SERT) transporters are not expressed in the liver 
(Eisenhofer, 2001, Ramamoorthy et al., 1993), leaving open to question the 
transporter(s) responsible for monoamine clearance in the human liver.  
Organic cation transporters (OCTs), a subset of the SLC22 superfamily of 
transporters, are polyspecific transporters that mediate the uptake of a wide variety of 
positively- and neutrally- charged compounds (Koepsell, 2013). Broad substrate 
specificity combined with tissue localization, primarily in detoxifying organs, has recently 
coupled OCTs to the elimination of several drugs and toxins as well as endogenous 
compounds (Koepsell et al., 2007, Nies et al., 2011). Expressed primarily in the liver, 
hOCT1 is involved in the hepatic elimination of numerous small molecules, and has 
been linked to the transport of biogenic amines. Previously, the rat organic cation 
transporter, rOCT1, was shown to transport catecholamines (Breidert et al., 1998, 




associated with neurotransmitter transport, however there exists some controversy in 
the literature as to substrate specificity and transport efficiency (Amphoux et al., 2006, 
Kerb et al., 2002, Lips et al., 2005). 
Moreover, the interference of drugs with endogenous neurotransmitter clearance, 
particularly at the transporter level, has not been investigated. While it is becoming 
increasingly necessary to identify transporter-mediated drug-drug interactions in the 
modern age of polypharmacy, little is currently known about the effects that therapeutics 
have on transport and elimination of endogenous substrates. To elucidate interactions 
of common medications and other xenobiotics with endogenous substrates of human 
OCT1, transport and inhibition of the biogenic amines dopamine, norepinephrine, and 
serotonin were characterized in both Human Embryonic Kidney 293 (HEK293) cells and 
primary human hepatocytes. 
 
2.2 MATERIALS AND METHODS 
2.2.1 Materials 
Radiolabeled [3H]-1-methyl-4-phenylpyridinium iodide (MPP+, 85.0 Ci/mmol) was 
purchased from American Radiolabeled Chemicals, Inc. (St. Louis, MO). Radiolabeled 
[3H]-dihydroxyphenylethylamine (dopamine, 46.0 Ci/mmol), [3H]-norepinephrine 
hydrochloride (14.9 Ci/mmol), and [3H]-hydroxytryptamine creatinine sulfate (serotonin, 
28.3 Ci/mmol) were purchased from Perkin Elmer (Boston, MA). NaCl was purchased 
from Amresco (Solon, OH). HEPES sodium salt and KCl were purchased from Fisher 




Chemicals (North York, ON, Canada). All other chemicals were purchased from Sigma-
Aldrich (St. Louis, MO). 
2.2.2 Cell Culture 
HEK293 cells were grown at 37ºC under humidified 5% CO2 in Dulbeccos’s 
Modified Eagle Medium (ATCC, Manassas, VA) supplemented with 10% fetal bovine 
serum (Sigma-Aldrich), 100 U/mL penicillin, and 100 µg/mL streptomycin (Invitrogen, 
Carlsbad, CA). Cells were seeded on 24-well plates coated with 0.1 mg/mL poly-D-
lysine (Invitrogen) at a density of 175,000 cells/well. Twenty-four hours after plating, 
cells were transiently transfected with pcDNA5/FRT (“empty vector”, Invitrogen) or 
pcDNA5/FRT-hOCT1 (“OCT1”) using the FuGENE HD transfection reagent (Promega, 
Madison, WI). Transfection mixtures contained 0.25 µg plasmid cDNA, 0.75 µL 
FuGENE HD, and Opti-MEM I + GlutaMAX–I (Invitrogen)  to a final volume of 25 µL per 
well. Transfected cells were incubated at 37ºC as above for 24 hours before use. 
Freshly isolated human hepatocytes seeded on collagen-coated 24-well plates at a 
density of 350,000 cells/well were obtained from the KUMC Department of 
Pharmacology, Toxicology and Therapeutics Cell Isolation Core lab. Hepatocytes were 
isolated from livers of male and female patients, with ages ranging from 30 to 57. 
2.2.3 Transport Assays 
HEK293 uptake assays were performed 24 hours post-transfection at 37ºC. 
Media were aspirated, and cells washed three times with warm (37ºC) uptake buffer 
(116 mM NaCl, 5.3 mM KCl, 1 mM NaH2PO4, 0.8 mM MgSO4, 5.5 mM D-glucose, and 




uptake buffer containing radiolabeled substrate and sufficient unlabeled substrate to 
reach the specified substrate concentration, as well as putative inhibitors (drugs) where 
indicated, for the specified amount of time. Transport for all substrates was measured 
within the initial linear time range (at 30 seconds for MPP+, and at five minutes for all 
other substrates). Uptake was terminated by washing four times with ice-cold uptake 
buffer. To quantify uptake, cells were lysed with 300 µL/well 1% TX-100 in PBS, of 
which 200 µL were transferred to 24-well scintillation plates (Perkin Elmer, Waltham, 
MA) and mixed with 750 µL Optiphase Supermix scintillation cocktail (Perkin Elmer). 
Radioactivity was measured using a MicroBeta Trilux liquid scintillation counter (Perkin 
Elmer). The remaining cell lysate was used for protein determination for normalization 
by BCA Protein Assay with bovine serum albumin standards (Pierce). Transporter-
specific uptake (net uptake) was determined by subtracting uptake into empty vector 
cells from the uptake into hOCT1-expressing cells. Each data point represents the 
average of three independent experiments, in which each condition was performed in 
triplicate. Transport assays were performed with hepatocytes between 20 and 24 hours 
after plating according to the method described above for HEK293 cells, using uptake 
buffer modified from Jigorel et al., (2005) (136 mM NaCl, 5.3 mM KCl, 1.1 mM KH2PO4, 
0.8 mM MgSO4, 1.8 mM CaCl2, 11 mM D-glucose, 10 mM HEPES, pH 7.4). Each data 
point represents the average of three independent experiments, in which each condition 
was performed in duplicate. 
2.2.4 Western Blotting 
Cultured cells and hepatocytes were lysed  in hypotonic homogenization solution 




IN) using a tissue homogenizer on ice. Lysates were subjected to centrifugation at 900 
g for 10 minutes, after which supernatant was collected and subjected to further 
centrifugation at 10,000 g for 20 min. The resulting pellets which contained protein-
enriched plasma membrane were resuspended in hypotonic homogenization solution 
including protease inhibitor, and protein concentration was determined by BCA protein 
assay (Pierce, Rockford, IL). Proteins (0.5 µg for HEK lysates, 50 µg for hepatocyte 
lysates) were resolved by SDS-PAGE on 4-15% Mini-PROTEAN® TGXTM 
polyacrylamide gels (Bio-Rad, Hercules, CA). Subsequently, proteins were transferred 
to nitrocellulose membrane. Immunoblotting was performed using standard procedures, 
with anti-OCT1 primary antibody (Novus Biologicals, Littleton, CO) at a concentration of 
1:2000, and HRP-conjugated secondary antibody at 1:10,000. Proteins were detected 
with ECL substrate (Pierce).  
2.2.5 Kinetic Analysis 
For kinetic analysis of serotonin transport, net uptake values from each individual 
experiment (n=3) were averaged, and the mean was analyzed by nonlinear regression 
and fit to the Michaelis-Menten equation to obtain maximal transport velocity (Vmax) and 
affinity constant (Km) using GraphPad Prism 6 (GraphPad Software Inc., La Jolla, CA). 
2.2.6 IC50 Determination 
For determination of IC50 values, net uptake from each individual experiment 
(n=3) was converted to percent of control. These values were averaged, and the mean 





2.2.7 Statistical Analysis 
Statistical significance was calculated using two-tailed unpaired t-tests. A P value 
<0.05 was considered significant. 
 
2.3 RESULTS 
2.3.1 Functional Characterization of Human OCT1 in Transiently-transfected 
HEK293 Cells 
To establish that our model of transient expression of hOCT1 in HEK293 cells 
was functional, transport of the model cation [3H]-1-methyl-4-phenylpyridinium (MPP+) 
was characterized. Initial time dependencies at low (0.5 µM) and high (100 µM) 
concentrations demonstrated uptake of MPP+ to be linear through one minute (Figure 
2.1) and kinetics experiments yielded a Km of 35 ± 7 µM and a Vmax of 500 ± 36 
pmol/mg protein/min (Figure 2.2). This compares well with previously published values 
(32 µM, Grundemann et al., 2003; 25 µM, Umehara et al., 2007) and suggested that our 
model of hOCT1 transport was functional and suitable for further experiments.  
2.3.2 hOCT1-mediated Neurotransmitter Transport 
In order to study the effect of drugs on hOCT1-mediated uptake of endogenous 
substrates, it was first necessary to identify suitable endogenous substrates. To 
establish monoamine neurotransmitters as substrates of hOCT1, transport of 100 µM 
(0.8 µCi/mL) [3H]-dopamine, [3H]-norepinephrine, and [3H]-serotonin was measured in 







Figure 2.1. Time-dependent uptake of MPP
+
 by hOCT1. HEK293-OCT1 and empty 
vector cells were incubated with (A) 0.5 µM, or (B) 100 µM radiolabeled MPP
+
 for given 
amount of time to determine the linear range of uptake. Each time point done in triplicate; 







Figure 2.2. Kinetics of hOCT1-mediated MPP
+
 uptake. HEK293-OCT1 and empty 
vector cells were incubated with increasing concentrations of radiolabeled MPP
+
 for 30 
seconds. The mean value (net uptake) ± SD for two independent experiments is shown.  






minutes. Uptake of these monoamines was significantly higher in hOCT1-expressing 
cells than in empty vector cells for all three neurotransmitters (Figure 2.3A). hOCT1-
mediated transport (net uptake) was obtained by subtracting the uptake into empty 
vector cells from that of hOCT1-expressing cells (Figure 2.3B). At a time point of five 
minutes, serotonin appeared to be the most efficiently transported substrate. Dopamine 
uptake was approximately 50% that of serotonin, while norepinephrine uptake was 
approximately 20% compared with serotonin. The observed norepinephrine uptake was 
minimal, and therefore unlikely to be physiologically relevant. Dopamine uptake by 
hOCT1, though significant, is again unlikely to be germane to the liver, due to low 
circulating levels of this neurotransmitter. Serotonin, however, is found at high 
concentrations in the gut and consequently portal blood levels are significantly higher 
than arterial blood, reportedly as much as three-fold, (Gershon and Tack, 2007, Toh 
1954), making it the best candidate of the three neurotransmitters to be transported by 
hOCT1 in vivo. Because of this, and the data suggesting that serotonin was the superior 
neurotransmitter substrate for hOCT1, serotonin was selected as the model 
endogenous substrate for further study. 
2.3.3 Kinetic Characterization of Serotonin Uptake by hOCT1 
To further characterize serotonin transport, uptake kinetics were performed. 
Serotonin influx was assessed in empty vector- and hOCT1-expressing cells after 
incubation with increasing concentrations of [3H]-serotonin, from 50 µM to 2 mM (0.8-2.0 







  Figure 2.3. Transport of serotonin, dopamine, and norepinephrine by hOCT1.  
(A) HEK293 cells transiently transfected with empty vector and hOCT1 plasmid were 
incubated with 100 µM radiolabeled serotonin, dopamine, or norepinephrine (0.8 µCi/mL) 
at 37ºC for five minutes. (B) hOCT-mediated uptake (net uptake) was determined by 
subtracting uptake into empty vector cells from that of hOCT1-expressing cells. Mean + 





to yield a Km of 197 ± 42 µM and Vmax of 561 ± 36 pmol/mg protein/min (Figure 2.4). 
These data suggest that serotonin is transported by hOCT1 with affinity and capacity 
comparable to other hOCT1 substrates. 
2.3.4 Inhibition of Serotonin Transport 
Because hOCT1 has moderate affinity for serotonin, it is feasible to hypothesize 
that hOCT1-mediated uptake of serotonin could be inhibited by drugs or other 
xenobiotics. To evaluate this, the following eight compounds were selected: acyclovir, 
cimetidine, diphenhydramine, fluoxetine, imatinib, metformin, tyramine, and verapamil. 
These potential inhibitors were selected based on previous reports that showed 
interactions with hOCT1 or serotonin-transporting proteins (Dresser et al., 2001, Nies et 
al., 2011, Sitte et al., 1998). Uptake of 200 µM (1.2 µCi/mL) serotonin was measured for 
five minutes at 37ºC in the absence and presence of 10 µM and 100 µM of each 
compound (Figure 2.5). While there appeared to be a trend of inhibition for almost all of 
the drugs screened, serotonin uptake was significantly (P<0.05) inhibited by 
diphenhydramine, fluoxetine, imatinib, and verapamil at both concentrations (Figure 
2.5). Inhibition by these four drugs was characterized further by determining IC50 values 
for serotonin transport (Figure 2.6). Transfected HEK293 cells were incubated with 100 
µM serotonin and increasing concentrations of each drug for five minutes at 37ºC. Net 
uptake was converted to percent of control and was analyzed by nonlinear regression to 
obtain IC50 values. IC50 values for diphenhydramine, fluoxetine, imatinib and verapamil 







Figure 2.4. Kinetics of hOCT1-mediated serotonin transport. Empty vector- and 
hOCT1-transfected HEK293 cells were incubated with increasing concentrations of 
radiolabeled serotonin, ranging from 50 µM (0.8 µCi/mL) to 2 mM (2.0 µCi/mL), for five 
minutes at 37ºC. Net uptake was fit to the Michaelis-Menten equation to obtain the affinity 
constant, Km = 197 ± 42 µM, and maximum transport velocity, Vmax = 561 ± 36 pmol/mg 







Figure 2.5. Inhibition of serotonin transport by common drugs. Transport of 200 µM 
radiolabeled serotonin (1.2 µCi/mL) was measured in HEK293 cells transfected with 
empty vector or hOCT1 plasmid cDNA in the presence of 10 µM or 100 µM drug for five 
minutes at 37ºC. DMSO controls were included at concentrations equivalent to those of 
imatinib preparations (≤ 1%). Mean ± SD of three independent experiments (net uptake) 






   
Figure 2.6. Concentration-dependent inhibition of serotonin uptake by hOCT1. In 
HEK293 cells transfected with empty vector or hOCT1, uptake of 100 µM radiolabeled 
serotonin (0.4 µCi/mL) was measured in the presence of increasing concentrations of (A) 
diphenhydramine, (B) fluoxetine, (C) imatinib, or (D) verapamil. Uptake values are 
expressed as percent of control and the mean ± SD of three independent experiments 





respectively. With IC50 values in the low micromolar range, all four drugs appear to be 
fairly potent inhibitors of hOCT1-mediated serotonin transport. 
2.3.5 Serotonin transport and inhibition in primary human hepatocytes 
To determine whether the observed transport and inhibition of serotonin is likely 
to be physiologically relevant, uptake and inhibition studies were conducted with freshly 
isolated and plated primary human hepatocytes. First, serotonin uptake into 
hepatocytes was assessed by incubating cells with 1.2 µCi/mL (42 nM) [3H]-serotonin at 
37ºC for five minutes (Figure 2.7A). Significant serotonin uptake was observed, even at 
this very low substrate concentration. To establish that the observed uptake of serotonin 
was carrier-mediated, hepatocytes were incubated with [3H]-serotonin in the presence 
of 1 mM unlabeled serotonin intended to inhibit any carrier-mediated transport of 
radiolabeled serotonin. Addition of 1 mM unlabeled serotonin decreased uptake of [3H]-
serotonin by more than 50% (Figure 2.7A), suggesting that the majority of serotonin 
uptake in hepatocytes is carrier-mediated. To confirm expression of hOCT1 in the 
hepatocytes used to measure serotonin transport, western blotting was performed using 
a commercially-available anti-OCT1 antibody. HEK-EV and HEK-OCT1 lysates were 
used as controls (Figure 2.7B). For each batch of hepatocytes, hOCT1 expression 
levels were high, and total hOCT1 expression was consistent between batches. Next, 
the ability of the four drugs to inhibit serotonin uptake into hepatocytes was investigated. 
Hepatocytes were incubated with [3H]-serotonin as described before in the presence of 
10 µM and 100 µM diphenhydramine, fluoxetine, imatinib, or verapamil (Figure 2.7C). 









Figure 2.7. Serotonin transport in primary human hepatocytes. (A) Between 20 and 
24 hours after plating, freshly isolated primary human hepatocytes were incubated for five 
minutes with 1.2 µCi/mL (radiolabeled only, 42 nM) serotonin. Carrier-mediated transport 
was inhibited by the presence of 1 mM unlabeled serotonin (right). (B) hOCT1 expression 
was confirmed in hepatocytes used to measure serotonin uptake. 50 µg of protein 
isolated from hepatocytes, was resolved by SDS-PAGE and blotted with anti-OCT1 
antibody; 0.5 µg of protein isolated from HEK293 cells transfected with empty vector 
(HEK-EV) and hOCT1 (HEK-OCT1) was included as control. (C) Drug-mediated inhibition 
of serotonin transport was conducted as in (A) in the presence of 10 µM and 100 µM 
diphenhydramine, fluoxetine, imatinib, or verapamil. DMSO controls were included at 
sufficient concentrations to match those in imatinib preparations. Net uptake is 







This study demonstrates that serotonin is a substrate of human OCT1 and, more 
importantly, that hOCT1-mediated serotonin transport can be inhibited by several 
commonly-prescribed drugs. Taken together, these findings suggest that hepatic 
clearance of endogenous substrates, including biogenic amines, can be affected by 
small molecule therapeutics at the transporter level. Our results illustrate that 
diphenhydramine, fluoxetine, imatinib, and verapamil inhibit serotonin uptake in hOCT1-
expressing HEK293 cells and in primary human hepatocytes.  
The liver has been established as a key organ in the elimination of endogenous 
compounds, including monoamine neurotransmitters, from the body. As previously 
mentioned, it is unlikely that hOCT1 plays a major role in the uptake of dopamine or 
norepinephrine in the liver, due to both low circulating concentrations and relatively low 
transport, as documented in Figure 2.3. However, the same cannot be said for 
serotonin. Approximately 95% of the body’s serotonin is synthesized and stored in the 
gut, where it is released to initiate peristalsis and activate secretory reflexes (Gershon 
and Tack, 2007). While the serotonin transporter (SERT) is expressed in the gut and 
functions in the reabsorption of released serotonin, a significant portion of serotonin 
reaches portal circulation; in fact, serotonin concentrations in portal blood can be as 
much as three-fold higher than in arterial blood (Toh, 1954). Additionally, the liver is 
responsible for the removal of up to 70% of the serotonin from portal blood (Thomas 
and Vane, 1967, Tyce, 1990). Given that SERT is not expressed in the liver 
(Ramamoorthy et al., 1993), we hypothesized that hOCT1 may be one transporter 




transport by hOCT1, though with conflicting results. Kerb et al., (2002) demonstrated 
serotonin transport by human OCT1 as a test probe for comparison of wild-type and 
polymorphic transporters. Conversely, Amphoux, et al., (2006) reported that human 
OCT1 showed very little specific transport of serotonin, among other neurotransmitters. 
However, Amphoux, et al,. also failed to show OCT3-mediated transport of several 
monoamines known to be OCT3 substrates, and those that were transported yielded Km 
values much higher than established elsewhere (Duan and Wang, 2010), suggesting a 
potential flaw in the employed expression system or other methods. In any case, we 
have demonstrated hOCT1-mediated serotonin transport in both HEK293 cells and in 
hepatocytes, confirming that serotonin is indeed a substrate of hOCT1, and our results 
indicate that hOCT1 is an important element in the elimination of serotonin from portal 
blood. 
While this study suggests that hOCT1 is a key component in hepatic elimination 
of serotonin, we cannot completely rule out minor contributions of other cation 
transporters that have also been reported to transport biogenic amines. Organic cation 
transporter 3 (OCT3) and plasma membrane monoamine transporter (PMAT) are both 
high-capacity neurotransmitter transporters and together comprise the “uptake2” 
mechanism for monoamine clearance in the brain (Wu et al., 1998, Zhou et al., 2007). 
Studies have shown that, in addition to hOCT1, both OCT3 and PMAT are expressed in 
the liver, though at very low levels. PMAT mRNA levels were nearly undetectable in the 
liver (Engel et al., 2004), suggesting its function pertains primarily to the brain, and 
hepatic OCT3 mRNA levels were shown to be between 6-30% that of hOCT1 (Chen et 




are relatively low (Duan and Wang, 2010) compared to that established in this study for 
hOCT1 (Figure 2.4). Combined, the low expression levels and relative transport 
affinities of OCT3 and PMAT suggest that they are likely minor components of serotonin 
uptake in hepatocytes, further solidifying the role of hOCT1 in serotonin elimination in 
the liver. 
Because hepatic clearance of serotonin may rely heavily on hOCT1 transport, it 
is important to understand the effects that drug interaction with hOCT1 has on serotonin 
uptake in the liver. The inhibition screen performed in this study (Figure 2.5) indicates 
that several drugs are capable of inhibiting serotonin transport by hOCT1.  
Diphenhydramine, fluoxetine, imatinib, and verapamil all significantly inhibited serotonin 
uptake in both HEK293 cells and human hepatocytes (Figures 2.5-2.7). Furthermore, 
even though uptake was not significantly inhibited, a trend of inhibition was observed for 
cimetidine and metformin, as well as the notorious monoamine neurotransmitter 
transporter inhibitor, tyramine. Additionally, IC50 values determined for 
diphenhydramine, fluoxetine, imatinib, and verapamil were all in the low micromolar 
range, 4.1 ± 1.4 µM, 6.2 ± 1.2 µM, 10.2 ± 1.2 µM, and 1.5 ± 1.4 µM respectively (Figure 
2.6). Given that substrate-dependent inhibition has been reported for OCT2 (Belzer et 
al., 2013) and MATE1 (Martínez-Guerrero and Wright, 2013), comparison of the IC50 
values obtained in the present study with previously reported values obtained using 
other substrates might give some insight into how different substrates are handled by 
hOCT1. Previously, diphenhydramine and fluoxetine inhibited MPP+ uptake with IC50’s 
of 3.4 µM and 2.8 µM, respectively (Müller et al., 2005, Haenisch et al., 2012), and 




values are comparable to the IC50 values we obtained for hOCT1-mediated uptake of 
serotonin, which suggests that serotonin and the two model substrates MPP+ and TEA 
are transported in a very similar way by hOCT1. In contrast, previous reports 
demonstrated that imatinib inhibited hOCT1-mediated metformin uptake with an IC50 
value of 1.5 µM (Minematsu and Giacomini, 2011), while in our study imatinib inhibited 
serotonin uptake with an IC50 value of 10.2 µM. This confirms the substrate-dependent 
inhibition seen with other organic cation transporters (Belzer et al., 2013, Martínez-
Guerrero and Wright, 2013) and suggests that these transporters have complex binding 
pockets, with different interaction sites for different substrates. Regardless, these novel 
results are strong evidence that xenobiotics may inhibit serotonin uptake in the liver, 
potentially hindering proper hepatic clearance of serotonin in vivo, and it is plausible that 
these same effects would be seen with other endogenous substrates as well. 
Undoubtedly, drug-mediated inhibition of serotonin transport would be dependent 
upon drug concentrations achieved in vivo. Peak plasma drug concentrations have 
been shown to reach 66 ng/mL (0.3 µM) for diphenhydramine, 302 ng/mL (1 µM) for 
fluoxetine, 3380 ng/mL (6.8 µM) for imatinib, and 400 ng/mL (0.9 µM) for verapamil 
(Blyden et al. 1986, Peng et al., 2004, U.S. NLM Daily Med a-b). These plasma levels 
are not necessarily high enough to elicit significant hOCT1 inhibition. However, in this 
case, because hOCT1 is localized to the liver, portal blood drug concentrations are 
likely more relevant. Though drug concentrations have not been measured in portal 
blood, it is likely that portal drug concentrations are significantly higher than those 
measured in plasma, given that all of the drugs tested are dosed orally. This suggests 




 Inhibition of serotonin uptake in the liver may bear several implications, including 
a potential increase in circulating serotonin levels as well as locally increased 
extracellular serotonin concentrations in the liver. Increased serotonin levels in the 
circulation has the potential to lead to certain specific toxicities, including alterations in 
the blood coagulation cascade. When activated, platelets degranulate, releasing a 
variety of factors, including serotonin, to initiate coagulation (Troxler et al., 2007). 
Recently, SSRIs have been shown to exert an anticoagulative effect, due to decreases 
in serotonin levels in the blood (Bottlender et al., 1998). Conversely, drug-mediated 
inhibition of serotonin uptake in the liver could increase blood serotonin levels, 
potentially resulting in hypercoagulopathy. In addition, increases in circulating serotonin 
has the potential to cause acute changes in blood pressure due to its vasoactive 
properties (Page and McCubbin, 1953, Rapport, 1949). Furthermore, serotonin has 
been implicated in changes in renal blood flow (Blackshear et al., 1986), which might 
suggest a role for increased circulating serotonin levels in kidney dysfunction. 
Additionally, the importance of serotonin in both liver injury and regeneration has 
recently been established. Work completed by Pierre-Alain Clavien and others exposed 
a critical function of serotonin in liver regeneration (Lesurtel et al., 2006, Nocito et al., 
2007b). Conversely, serotonin has also been implicated in mitochondrial dysfunction 
and hepatocellular injury in nonalcoholic steatohepatitis (NASH) (Nocito et al., 2007a). 
Inhibition of serotonin transport by hOCT1 could potentiate the pathogenesis of NASH. 
In contrast, increased serotonin levels in resection patients could be beneficial for liver 
regeneration. In any case, drug-mediated inhibition of serotonin uptake by hOCT1 may 




In conclusion, we have established that serotonin is a viable substrate for human 
OCT1, and more importantly, that commonly-prescribed drugs inhibit its uptake. 
Diphenhydramine, fluoxetine, imatinib, and verapamil significantly inhibited serotonin 
transport in both HEK293 cells and in primary human hepatocytes. Moreover, these 
compounds appear to be fairly potent inhibitors of serotonin uptake, as IC50 values were 
determined to be in the low micromolar range for all four drugs. The implications of 
serotonin uptake inhibition in the liver may be several, and the results of this study bring 
new insights to the potential for drugs and other xenobiotics to interfere with 
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The human organic cation transporter 1 (hOCT1) is a liver-specific drug 
transporter that mediates the uptake of numerous drugs and endogenous compounds 
into the liver for metabolism and/or excretion. Its location and function makes it a prime 
candidate for drug-drug interactions (Bachmakov, et al., 2008, Cho, et al., 2014, Choi, 
et al., 2010, Minematsu and Giacomini, 2011). As such, regulatory agencies include 
hOCT1 inhibition studies in their recommended preclinical testing of new drug 
candidates (European Medicines Agency, 2012). 
Recently, substrate-dependent interactions have been described for several drug 
transporters, including close relatives of hOCT1. For example, when incubated with 
OATP1B3, the antifungal drug clotrimazole strongly inhibits uptake of substrate Fluo-3, 
stimulates uptake of estradiol-β17-glucuronide, but exhibits no effect on estrone-3-
sulfate uptake (Gui, et al., 2008). Similar substrate-dependent effects were described 
for green tea catechins interacting with OATP1B3 (Roth, et al., 2011). Several studies 
identified substrate-dependent modulation for hOCT2, a member of the same subfamily 
of transporters and which shares 70% sequence identity with hOCT1 (Gorboulev, et al., 
1997). Zolk, et al., (2009) demonstrated that several structurally diverse compounds 
were markedly more potent inhibitors of hOCT2-mediated uptake of metformin than 
MPP+, as determined by IC50 values. In addition, widely-varied IC50 values were 
observed for hOCT2 inhibitors when screened against MPP+ versus novel substrate 
NBD-MTMA (Belzer, et al., 2013). Furthermore, Hacker, et al., (2015) compared the 




metformin, and observed that several of the tested compounds only inhibited one or two 
substrates. 
Recent publications also indicate the possibility of substrate-dependent effects 
for hOCT1. A previous publication from our lab demonstrated that acyclovir, cimetidine, 
and metformin, all reported substrates or inhibitors of hOCT1, did not inhibit serotonin 
uptake (Boxberger, et al., 2014). Also, in our hands, imatinib elicited a 10-fold higher 
IC50 with serotonin employed as probe substrate versus that published using metformin 
as probe substrate (Minematsu and Giacomini, 2011). Additionally, IC50 values 
determined for MPP+, TEA, and cimetidine were much higher when ethidium was used 
as probe substrate than previously reported values utilizing other probe substrates (Lee, 
et al., 2009). Furthermore, quercetin and lamivudine did not inhibit hOCT1-mediated 
transport of MPP+ (Mandery, et al., 2012) and TEA (Moss, et al., 2015), respectively, 
despite being substrates of hOCT1 (Glaeser, et al., 2014, Jung, et al., 2008, Minuesa, 
et al., 2009). While it is difficult to directly compare IC50 values between laboratories due 
to inter-assay variability, all of these studies taken together with reports that describe 
multiple binding sites and/or translocation pathways within hOCT1 (Chen, et al., 2017, 
Ciarimboli, et al., 2004, Ciarimboli and Schlatter, 2005, Koepsell, et al., 2003) strongly 
suggest the potential for substrate-dependent modulation of hOCT1. 
If substrate-dependent interactions occur with hOCT1, guidelines recommending 
inhibition studies utilizing one or two model probe substrates (European Medicines 
Agency, 2012) may not be sufficient to identify potentially dangerous drug-drug 
interactions. Therefore, concrete identification of substrate-dependent effects of hOCT1 




hOCT1 with competitive counterflow (CCF) experiments, utilizing multiple hOCT1 probe 
substrates and numerous known ligands, and explored the observed interactions 
through homology modeling and docking studies.  
 
3.2 MATERIALS AND METHODS 
3.2.1 Materials 
[3H]-1-methyl-4-phenylpyridinium iodide (MPP+, 85.0 Ci/mmol), and [14C]-
metformin (0.1 Ci/mmol) were purchased from American Radiolabeled Chemicals, Inc. 
(St. Louis, MO). [3H]-hydroxytryptamine creatinine sulfate (serotonin, 28.3 Ci/mmol), and 
[14C]-tetraethylammonium bromide (3.5 mCi/mmol) were purchased from Perkin Elmer 
(Boston, MA). [3H]-bromosulfophthalein (BSP, 11.5 Ci/mmol) was purchased from 
International Isotopes Clearing House, Inc. (Shawnee Mission, KS). Sodium chloride, 
potassium chloride, and ethidium bromide were obtained from Fisher Scientific 
(Waltham, MA). Dolutegravir was purchased from Advanced ChemBlocks (Burlingame, 
CA). Prostaglandin E2 and imatinib were purchased through Toronto Research 
Chemicals (Toronto, ON, Canada). Erlotinib, gefitinib, and oxaliplatin were obtained 
from the NCI/DTP Open Chemical Repository (http://dtp.cancer.gov) as part of the 
approved oncology drug set II library. All other chemicals were purchased from Sigma-
Aldrich (St. Louis, MO). 




Flp-InTM-293 cells (Invitrogen, Carlsbad, CA), derived from Human Embryonic 
Kidney (HEK) cells, were cultured in Dulbecco’s Modified Eagle’s medium (ATCC, 
Manassas, MA) supplemented with 10% fetal bovine serum (Sigma-Aldrich), 100 U/mL 
penicillin and 100 µg/mL streptomycin (Sigma-Aldrich), and 100 µg/mL Zeocin 
(Invitrogen) at 37°C under humidified 5% CO2. Per manufacturer’s protocol, to generate 
HEK–EV and –hOCT1 cells, Flp-InTM-293 cells were co-transfected with pcDNA5/FRT 
plasmid (empty vector, EV) or pcDNA5/FRT-hOCT1 (hOCT1) plasmid, respectively, and 
pOG44 using FuGENE HD® transfection reagent (Promega, Madison, WI). After 
transfection, cells were grown in medium, using conditions described above, with 
hygromycin (100 µg/mL, Invitrogen) replacing Zeocin to select for stable transfectants. 
Colonies were isolated and propagated through clonal expansion. Clones were assayed 
for hOCT1 transport activity.  HEK-hOCT1 clones, which demonstrated high transport of 
[3H]-MPP+, and HEK-EV clones, which did not show significant uptake of [3H]-MPP+ 
were selected, expanded, frozen, and stored per manufacturer protocol for future use. 
Cells were seeded on 48-well plates coated with 0.1 mg/mL poly-D-lysine (Invitrogen) at 
a density of 160,000 cells/well, and incubated at 37°C for approximately 48 hours until 
confluency was reached. For BSP transport assays, cells were seeded on 24-well 
plates coated with 0.1 mg/mL poly-D-lysine (Invitrogen) at a density of 250,000 
cells/well, and incubated as described above. 
3.2.3 Transport Assays 
Transport assays were performed approximately 48 hours after cells were plated. 
All assays (excluding BSP transport assays) were performed at room temperature, 




mM MgSO4, 1.5 mM CaCl2, 5 mM D-glucose, and 12.5 mM HEPES, adjusted to pH 7.4 
with Tris base) to prewash cells, and ice-cold uptake buffer to stop transport. BSP 
transport assays were performed at 37°C, using pre-warmed uptake buffer to prewash 
the cells. Buffer components (with the addition of bovine serum albumin, during washes 
only, to limit non-specific binding of BSP) and stop conditions were as described above. 
Time-dependent uptake was measured by incubating HEK-EV and -hOCT1 cells 
with 150 µL of uptake buffer containing radiolabeled [3H]-MPP+ (0.4 µCi/mL), [3H]-
serotonin (0.4 µCi/mL), [14C]-metformin (0.2 µCi/mL), or [14C]-TEA (0.2 µCi/mL) for 30 
seconds to 180 minutes. Net uptake was calculated by subtracting uptake into HEK-EV 
cells from that of HEK-hOCT1 cells. 
Competitive counterflow (CCF) experiments involved pre-loading HEK-hOCT1 
cells with radiolabeled probe substrates (as described above) for 90 minutes. Following 
preload incubation, 1.5 µL of concentrated efflux solution containing water (control) or 
unlabeled test compound was added to the wells and plates were vortexed briefly on 
low to initiate efflux. Compounds used to induce CCF were ideally employed at 
concentrations 10-fold higher than published Km values (see Table 3.1 for 
concentrations of test compounds employed). For time-dependent efflux, cells were 
incubated with efflux solutions for 15 seconds to 10 minutes. For CCF assays, cells 
were incubated with efflux solutions for 30 seconds (MPP+) or 5 minutes (serotonin, 
TEA).  
Once the assays were complete, all cells were lysed with 150 µL/well for 48-well 

















MPP+ 15, 32, 35 
Boxberger, et al., 2014, 
Grundemann, et al., 
2003, Zhang, et al., 
1997b 
0.1 0.1 
Serotonin 197 Boxberger, et al., 2014 1 1 
Metformin 1470 Kimura, et al., 2005 10 10 
TEA 168, 229 
Bednarczyk, et al., 2003, 
Zhang, et al., 1998 
1 1 
BSP ---b  1 0.59 
Glucose ---b  1 1 
Acyclovir 151 Takeda, et al., 2002 1 1 
Dolutegravir ---b  1 1 
Ritonavir [5] Zhang, et al., 2000 0.1 0.1 
Lamivudine 249, 1250 
Jung, et al., 2008, 
Minuesa, et al., 2009 
1 1 
Cimetidine [95], [166] 
Ciarimboli, et al., 2004, 
Zhang, et al., 1998 
10 10 
Ranitidine [22], 70 
Bednarczyk, et al., 2003, 
Bourdet, et al., 2005 
1 1 
Famotidine [28] Bourdet, et al., 2005 1 1 
Diphenhydramine [4] 
Boxberger, et al., 2014, 
Muller, et al., 2005 
0.1 0.1 
Imatinib [0.1], [1.5], [10] 
Boxberger, et al., 2014, 
Minematsu and 
Giacomini, 2011, Nies, 










Oxaliplatin [4]c Zhang, et al., 2006 0.1 0.1 
Verapamil [1.5], [1.8], [3] 
Boxberger, et al., 2014, 
Dickens, et al., 2012, 





Midazolam [3.7] Zhang, et al., 1998 0.1 0.1 
Fluoxetine [3], [6] 
Boxberger, et al., 2014, 
Haenisch, et al., 2012 
0.1 0.1 
Lamotrigine 62 Dickens, et al., 2012 1 1 
Acebutolol HCl [96] Zhang, et al., 1998 1 1 
Salbutamol [277] Salomon, et al., 2015 1 1 
Thiamine [434], 780 
Bednarczyk, et al., 2003, 
Chen, et al., 2014 
10 10 
Prostaglandin E2 [0.7] Kimura, et al., 2002 0.1 0.1 
EGCG [140]d Knop, et al., 2015 1 0.93 
Quercitin 2.2 Glaeser, et al., 2014 0.1 0.1 
Berberine 15 Nies, et al., 2008 0.1 0.09 
Ethidium 0.8 Lee, et al., 2009 0.1 0.1 
 
a
 In some instances, actual concentration varied from desired concentration due to solubility issues when 
preparing stock solutions. 
b
 Affinity has not been determined for hOCT1. 
c
 IC50 determined by cytotoxicity. 
d




of each lysate was transferred to a 96- or 24-well scintillation plate (Perkin Elmer, 
Waltham, MA), and mixed with 100 or 300 µL Optiphase HiSafe 3 scintillation cocktail 
(Perkin Elmer). Radioactivity was determined by liquid scintillation counting using a 
MicroBeta Trilux liquid scintillation counter (Perkin Elmer). Where protein concentration 
was determined, protein was measured in duplicate for each condition on 96-well plates 
using the Pierce BCA assay (Thermo Fisher Scientific, Waltham, MA). Each data point 
represents the average of three independent experiments, wherein each condition was 
completed in triplicate. 
3.2.4 Determination of Kinetic Parameters 
To determine kinetic parameters, net uptake values, obtained by subtracting 
uptake into HEK-EV cells from that of HEK-hOCT1 cells, from each of three 
independent experiments were averaged and plotted using GraphPad Prism 6 
(GraphPad Software Inc., La Jolla, CA). Subsequently, the data were analyzed by 
nonlinear regression and, for kinetics analysis, fit to the Michaelis-Menten equation. 
3.2.5 Generation of a hOCT1 Homology Model 
A homology model of human hOCT1 (GenPept accession #: O15245) was 
prepared using the BIOVIA Discovery Studio’s version 4.5 (http://accelrys.com/) BHM 
(Build Homology Models) protocol, which supports a software plugin for UCSF Modeller 
automodel, ver. 9.14 (https://salilab.org/modeller/contact.html). Chain A of the crystal 
structure of the bacterial glycerol-3-phosphate transporter from E.Coli, GlpT (PDB ID # 
1PW4_A; Huang, et al., 2003), was used as an input template. The GlpT transporter 




approximately 18% sequence identity (~50% sequence similarity) to hOCT1, and 
functionally parallels hOCT1 in regards to its propensity for substrate promiscuity. In 
order to facilitate efficient modeling of the hOCT1 transporter, the large extracellular 
loop region between helical TMDs 1 and 2, and the intercellular loop region between 
helical TMDs 6 and 7, were both removed from the structure prior to model construction. 
Parameters in the Parameters Explorer box of the BHM menu in Discovery Studio were 
set to the following: Cut Overhangs was set to True in order to cut the terminal residues 
of the input model sequence that did not align properly with the input templates, Number 
of Models was set to 5 in order to define the number of models to create from an initial 
structure, and the Optimization Level was set to Low in order to specify the amount of 
molecular dynamics to perform with simulated annealing.  
In order to build refinement models on the detected loop regions, i.e., the model 
sequence segments of at least 5 residues length which are not specifically aligned with 
the templates, the LOOPER function was used to systematically search loop 
conformations and rank them using CHARMm, with Refine Loops set to True. The BHM 
protocol uses the DOPE (Discrete Optimized Protein Energy; Shen and Sali, 2006) 
method to refine loops, which results in a more energetically accurate portrait of the 
loop structure. Refine Loops, Number of Models was set to 5 to specify the number of 
models to be created by loop optimization, and the Refine Loops Optimization Level 
was set to Low. Refine Loops with the DOPE method was set to High Resolution. After 
running the BHM protocol, the Best Model Structure Superimposed to Templates was 
chosen from the generated output models for the final three-dimensional model 




3.2.6 Docking of Ligands into the hOCT1 Homology Model 
In order to identify the potential binding modes and protein interaction sites of 
various ligands with hOCT1, an in silico molecular docking strategy was employed using 
the UCSF DOCK 6.7 software suite, under academic license (University of California, 
San Francisco: http://dock.compbio.ucsf.edu/DOCK_6/index.htm; Allen, et al., 2015, 
Fan, et al., 2009, Huang, et al., 2006). The 3D conformer for each ligand was 
downloaded directly from the PubChem website (https://pubchem.ncbi.nlm.nih.gov/), 
parameterized for partial charges, and used for all docking studies described below. 
Extraneous information not required for the docking simulation, including the headers, 
connect records, and waters, were deleted from the PDB text file. Additionally, all 
hydrogens were removed from the receptor using the SELECT function from the UCSF 
Chimera 1.11.2 software suite (Pettersen, et al., 2004).  
The hOCT1 receptor was then prepared for docking by using the UCSF Chimera 
1.11.2 DOCK PREP function. Once preparation of the receptor had been completed, it 
was saved in the MOL2 format. Sphere generation was accomplished by inputting a dot 
molecular surface (DMS) parameterization of the receptor surface into the SPHGEN 
module of the DOCK software suite. The DMS parameterization is accomplished by 
rolling a ball the size of a water molecule over the Van der Waal's surface of the 
receptor. The surface normal vector at each surface point is computed and used to 
calculate the size of each sphere generated. After initial sphere generation, the total 
number of sphere clusters was pruned to only the clusters representing the active site of 
the protein using the DOCK SHOWSPHERE module. This resulted in the largest sphere 




generated by enclosing the spheres in a rectangular box and using the GRID utility to 
obtain files representing both the electrostatic and Van der Waals forces according to 

















where each term is a double sum over ligand atoms i and receptor atoms j, Aij and Bij 
are the attraction and repulsion parameters, respectively, r is the distance between the 
van der Waals radii of particles i and j in the case of repulsion a or attraction b, q is the 
electrostatic surface potential of i or j, and D is the well depth of the interaction between 
the ligand and receptor atoms, as defined by Kuntz, et al., (1982). The GRID utility then 
generated files representing the contact score and the energy score which are utilized in 
the docking routine. The final size of the docking grid box was 16.7 Å x 25.9 Å x 16.7 Å. 
The docking parameters were as follows: maximum number of orientations was set to 
between 50 and 1000, Van der Waals energy component from between 20 to 25, and 
maximum number of iterations to 500 (except for berberine, which was set to 1,000). 
The VIEWDOCK utility of UCSF Chimera 1.11.2 was used for visualization of the 
docking poses and measuring distances and angles between atoms of interest. 
 
3.3 RESULTS 




HEK293 cells were used to generate stable cells lines containing pcDNA5/FRT 
empty vector (control) and pcDNA5/FRT-hOCT1 vectors using the Flp-InTM system. 
Clones stably-expressing hOCT1 were assayed for transport of model cation MPP+ and 
probe substrate serotonin (Figure 3.1). Significant uptake of both substrates was 
observed in the selected hOCT1-expressing cells at multiple time points, compared to 
control cells, demonstrating adequate functionality of the stably-expressed transporters. 
3.3.2 Substrate-dependent Interactions with hOCT1 as Determined by Competitive 
Counterflow 
To characterize the previously observed putative substrate-dependent 
interactions of hOCT1, the competitive counterflow (CCF) assay, developed by Harper 
and Wright (2013), was employed. CCF capitalizes on the observation that OCTs 
transport substrates in both directions, and therefore can function as exchangers by 
transporting one substrate into the cell and subsequently effluxing another from the 
cytoplasm. In this study, CCF was employed to examine substrate-dependent effects by 
utilizing four different radiolabeled probe substrates: MPP+, serotonin, metformin, and 
TEA.  
Before CCF could be performed, the time point where substrate transport 
reached steady-state equilibrium needed to be determined. For this, time-dependent 
uptake assays were performed for all four substrates (Figure 3.2A-D). MPP+, metformin, 
and TEA uptake reached steady-state by 60 minutes, while serotonin uptake plateaued 
around 90 minutes. Therefore, pre-load incubations prior to CCF were done for 90 














Figure 3.1. Uptake of MPP
+
 and Serotonin by HEK-EV and -hOCT1 stable 
transfectants. To functionally validate the generated HEK-EV (empty vector) and  
-hOCT1 stable cell lines, cells from each pool were incubated with radiolabeled (A) MPP
+
 
(0.9 µCi/mL, 11 nM) and (B) serotonin (1.2 µCi/mL, 42 nM) at 37°C for the indicated 




















Figure 3.2. Time-dependent uptake and efflux of MPP
+
, serotonin, metformin, and 
TEA by hOCT1. To establish the time when hOCT1 transport reaches steady-state, 
HEK-EV and -hOCT1 cells were incubated with radiolabeled (A) MPP
+
 (0.4 µCi/mL, 4.7 
nM), (B) serotonin (0.4 µCi/mL, 14 µM), (C) metformin (0.2 µCi/mL, 2 µM), or (D) TEA 
(0.2 µCi/mL, 54 µM) at room temperature for 15 seconds to 180 minutes. Once steady-
state was determined, HEK-hOCT1 cells were pre-loaded with (E) MPP
+
 (0.4 µCi/mL, 4.7 
nM), (F) serotonin (0.4 µCi/mL, 14 µM), (G) metformin (0.2 µCi/mL, 2 µM), or (H) TEA 
(0.2 µCi/mL, 54 µM), for 90 minutes to reach equilibrium, at which point CCF (efflux) was 
initiated by adding unlabeled MPP
+
 (100 µM), serotonin (1 mM), metformin (10 mM), or 
TEA (1 mM) to each well and incubated for 15 seconds to 10 minutes (2 minutes for 
MPP
+
). Each condition was done in triplicate and the mean ± SD of three independent 






was performed with all four substrates, using unlabeled MPP+, serotonin, metformin, 
and TEA as the efflux solution for their respective pre-load substrates. As can be seen 
in Figure 3.2E-H, maximum efflux was reached by 30 seconds for MPP+, and 5 minutes 
for serotonin and TEA. Interestingly, unlabeled metformin did not induce efflux of 
radiolabeled metformin at any time point measured (Figure 3.2G). This may suggest a 
metformin “sink” within the cell. In any case, because of this, metformin was excluded 
as a probe substrate for further CCF studies, and 30 seconds (MPP+) and 5 minutes 
(serotonin and TEA) were used as CCF efflux time points. 
For CCF, several known hOCT1 substrates and inhibitors were employed as test 
compounds, as well as some compounds which haven’t been tested for interactions 
with hOCT1. MPP+, serotonin, metformin, and TEA were used as positive controls for 
efflux, while glucose and bromosulfophthalein (BSP) were selected as negative 
controls, as glucose does not interact with hOCT1 and as a negatively-charged 
molecule, BSP is not expected to interact. A “cut-off” value for efflux was set at 80% 
substrate content to distinguish substrates from non-substrates.  
Because the maximum efflux varied for each of the pre-load substrates, as seen 
in Figures 3.2E-G and 3.3A, a correction factor for CCF efflux values was necessary to 
compare the efficiency of efflux elucidated by the test compounds for each probe 
substrate. The data shown in Figure 3.3B were corrected for the observed differences in 
maximum efflux between probe substrates by setting the observed value of substrate 
content when TEA and thiamine were employed as test compounds as the maximum 





Figure 3.3. Substrate-dependent ligand interactions as determined by competitive 
counterflow. HEK-hOCT1 cells were pre-loaded with radiolabeled MPP
+
 (0.4 µCi/mL, 4.7 
nM; black bars), serotonin (0.4 µCi/mL, 14 nM; hatched bars), or TEA (0.05 µCi/mL, 14 
µM; grey bars) for 90 minutes to reach equilibrium. CCF was initiated by adding 
unlabeled test compounds at concentrations approximately equal 10-times the published 
Km values for hOCT1 (see Table 3.1 for concentrations used) to the respective wells. 
CCF was measured for 30s when MPP
+
 was employed as the pre-load substrate, and 5 
minutes when serotonin and TEA were used. Raw data are shown in panel (A).The data 
shown in (B) corrects for the observed differences in maximum efflux between pre-load 
substrates. Each condition was done in triplicate and the mean ± SD of three 






assigned “cut-off” value from 80% (uncorrected data, Figure 3.3A) to 65% (corrected 
data, Figure 3.3B). 
As expected, MPP+, serotonin, metformin, and TEA induced efflux of all three 
probe substrates, as did thiamine (Figure 3.3). Interestingly and unexpectedly, BSP also 
induced efflux of all three substrates, indicating that BSP may be a substrate of hOCT1. 
Lamivudine, ranitidine, famotidine, diphenhydramine, fluoxetine, and berberine all 
induce efflux of radiolabeled MPP+ and serotonin, but not TEA (Figure 3.3). The 
remaining test compounds did not induce efflux of any of the probe substrates. 
3.3.3 Characterization of hOCT1-mediated Bromosulfophthalein Uptake 
To confirm the results of the CCF assay, which suggested that BSP is a substrate of 
hOCT1, direct uptake studies using [3H]-BSP were performed. Time-dependent uptake 
studies using 0.1 µM and 50 µM BSP demonstrated an increase of uptake into HEK-
hOCT1 cells over HEK-EV cells by five minutes (Figure 3.4A-B), indicating that BSP is 
indeed a substrate for hOCT1. Kinetics analysis was then performed to further 
characterize BSP transport by hOCT1 (Figure 3.4C). Michaelis-Menten analysis yielded 
a Km of 13.6 ± 2.6 µM and Vmax of 55.1 ± 4.1 pmol/mg protein/min for BSP. 
3.3.4 Computational Modeling of Ligand Interactions 
To further investigate the observed interactions in the CCF assay, we constructed a 
hOCT1 homology model and performed in silico docking of several of the employed test 
compounds. The hOCT1 homology model generated by BIOVIA Discovery Studio’s 
UCSF Modeller automodel plug-in produced 9 helical TMD regions with an inward 







Figure 3.4. Bromosulfophthalein is a substrate of hOCT1. HEK-EV and -hOCT1 cells 
were incubated in the presence of (A) 0.1 µM (0.3 µCi/mL) or (B) 50 µM (0.9 µCi/mL) 
radiolabeled BSP for increasing amounts of time to demonstrate time-dependent transport. 
To evaluate the kinetic parameters of BSP transport, (C) HEK-EV and -hOCT1 cells were 
incubated with increasing concentrations of radiolabeled BSP, ranging from 0.1 µM (0.3 
µCi/mL) to 50 µM (0.9 µCi/mL), for 2 minutes at 37ºC. Net uptake, obtained by subtracting 
uptake in empty vector cells from that of hOCT1-expressing cells, was fit to the Michaelis-
Menten equation to obtain a Km of 13.6 ± 2.6 µM and Vmax of 55.1 ± 4.1 pmol/mg 
protein/min. Each condition was completed in triplicate and the plotted values ± SD are the 













Figure 3.5. Homology model of hOCT1. A homology model for hOCT1 was constructed 
using BIOVIA Discovery Studio’s UCSF Modeller. Chain A of the GlpT (E.coli) crystal 
structure served as the input template from which this model was built. The model 
excludes the extracellular loop between TMD 1 and 2, and the intracellular loop between 






homology models have been constructed using both the E. coli lactose permease, LacY 
(Popp, et al., 2005), and more recently, the high affinity phosphate transporter from 
Piriformospora indica, PiPT (Chen, et al., 2017). Our rationale in choosing the GlpT 
protein was that it, and PiPT, are more functionally similar to hOCT1 in that they both 
transport ions that are charged at physiological pH (cations in the case of hOCT1, and 
anions in the cases of GlpT and PiPT), in contrast to LacY, which transports uncharged 
lactose and closely-related analogues. The structural model of hOCT1 was well 
resolved and overall closely resembled the tertiary structure of GlpT. In particular, 
residues W218, Y222, and T226 are all located in TMD4, with their respective side 
chains pointed toward the interior of the translocation channel. These residues were 
previously implicated in substrate translocation via site-directed mutagenesis 
experiments (Gorboulev, et al., 2005). Similarly, I443, I447, and Q475, which are also 
implicated in substrate translocation (Gorboulev, et al., 1999), are located in TM helix 
10, again near the putative active site cavity. These results increased our confidence in 
the accuracy of the homology model for use as a docking template. 
In order to understand the structural implications of multiple ligand modulation of 
hOCT1 transport activity, we used our constructed hOCT1 homology model as a 
receptor template to dock several of the more interesting drugs that demonstrated 
significant differences in the CCF assay. The majority of compounds tested in the CCF 
assay (MPP+, serotonin, TEA, metformin, BSP, acyclovir, ritonavir, lamivudine, 
cimetidine, famotidine, imatinib, fluoxetine, lamotrigine, thiamine, prostaglandin E2, 
quercetin, berberine, and ethidium) were docked into the homology model using UCSF 



















Figure 3.6. Ligand structures docked into hOCT1 homology model. The chemical 
structures of ligands yielding interesting results in the CCF assay were docked into a 
hOCT1 homology model using UCSF DOCK. These ligands included: MPP
+
, serotonin, 
metformin, TEA, BSP, acyclovir, ritonavir, lamivudine, cimetidine, famotidine, imatinib, 
fluoxetine, lamotrigine, thiamine, PGE2, quercetin, berberine, and ethidium. (A) The 
chemical structures are shown in multiple colors within the pore of the transporter, which 
is shown as a grey mesh of the van der Waals surface of the transporter. (B) The van der 
Waal’s surfaces of the docked ligands are illustrated magenta (BSP) and blue (remaining 
ligands docked), and the backbone structure of protein shown in grey. The equivalent of 
one helix was removed from these graphics to better visualize the ligand structures. With 
the exception of BSP, all 19 ligands included in the docking study docked within a central 





model, exhibited as a mesh of the protein surface. All ligands, with the exception of 
BSP, docked within the putative translocation pore, in close proximity to residues that 
are crucial for transporter-ligand interactions (e.g., W218, Y222, T226, I443, I447, and 
Q475), further enhancing our confidence in the structural validity of the hOCT1 
homology model. This can be viewed more clearly in Figure 3.6B, which reveals 
putative binding pockets within the transporter (grey ribbon) shown as the van der 
Waals surfaces of all the ligand structures docked. 
Interestingly, most docked ligands, with the exception of BSP, appeared to 
segregate into three categories: 1) those that docked in a binding site overlapping with 
MPP+, 2) those that docked in a binding site overlapping with TEA, and 3) those that 
overlapped with the binding site of acyclovir. BSP was an outlier from all the other 
ligands in that it bound to the hOCT1 receptor outside the confines of the translocation 
channel (Figure 3.6), likely due to its inherent negative charge, and, therefore, was not 
considered further. These observations led us to identify three distinct, but not mutually 
exclusive, ligand binding sites within the substrate translocation channel: the “MPP+ 
binding pocket”, the “TEA binding pocket”, and the “acyclovir binding pocket”. These 
separate binding pockets are illustrated in Figure 3.7, as both the chemical structures of 
ligands docked within the ribbon structure (Figure 3.7A,C), and the van der Waal’s 
surface of residues lining the binding regions (Figure 3.7B,D). These pockets were 
defined by residues Y240, Q241, F244, E386, I446, S470, and C473 (“MPP+ pocket”), 
A33, C36, V359, L360, C473, D474, G477, and I478 (“TEA pocket”), and Q362, G363, 
N374, L377, D378, Y381, and A383 (“acyclovir pocket”), all located within 3Å of the 




                 
 






Figure 3.7. Ligands docked in disparate pockets within hOCT1 homology model. In 
general, all ligands docked within one of three separate “binding pockets”. These pockets 
are demonstrated here by (A,C) the chemical structures and (B,D) the van der Waal’s 
surface of amino acid residues lining the binding pockets of MPP
+
 (yellow), TEA (red), 
and acyclovir (green). A portion of one helix was removed from (A) to better visualize the 
MPP
+





within each pocket and various ligand-specific properties which identified trends for 
each binding site. These aspects are addressed further in the Discussion. 
3.4 DISCUSSION 
Substrate-dependent interactions have been confirmed for several drug 
transporters, including close relatives of hOCT1 (Belzer, et al., 2013, Martínez-Guerrero 
and Wright, 2013, Noe, et al., 2007, Roth, et al., 2011), and as discussed in the 
introduction, a number of studies suggest substrate-dependent effects for hOCT1. This 
study identified substrate-dependent interactions for several hOCT1 ligands and 
employed computer modeling simulations to predict the structural basis underlying 
potential mechanisms. 
The CCF assay employed in this study was originally developed to identify novel 
substrates (Harper and Wright, 2013). As discussed previously, for the purpose of our 
study, a “cut-off” value of 80% efflux for the uncorrected data (Figure 3.3A) or 65% for 
corrected values (Figure 3.3B) was used to distinguish substrates from non-substrates. 
Based on the CCF results, MPP+, serotonin, metformin, TEA, BSP, lamivudine, 
ranitidine, famotidine, diphenhydramine, fluoxetine, thiamine, and berberine were all 
identified as substrates, given that they induced efflux of at least one radiolabeled probe 
substrate. MPP+, serotonin, metformin, TEA, lamivudine, ranitidine, famotidine, 
thiamine, and berberine were all previously reported as substrates (Bourdet, et al., 
2005, Boxberger, et al., 2014, Chen, et al., 2014, Gorboulev, et al., 1997, Jung, et al., 
2008, Kimura, et al., 2005, Nies, et al., 2008). This study confirms their status as such. 




diphenhydramine and fluoxetine as novel substrates of hOCT1. Diphenhydramine and 
fluoxetine have been reported to interact with hOCT1 in the past (Boxberger, et al., 
2014, Haenisch, et al., 2012, Muller, et al., 2005). However we are the first to 
demonstrate that BSP, a molecule which possesses two negative charges at 
physiological pH, interacts with and is transported by hOCT1. The importance of this 
novel substrate will be discussed further below. 
Acyclovir, ritonavir, cimetidine, imatinib, gefitinib, erlotinib, oxaliplatin, verapamil, 
midazolam, lamotrigine, acebutolol, salbutamol, prostaglandin E2, EGCG, quercetin, 
and ethidium did not elicit significant efflux (Figure 3.3). Interestingly, acyclovir, imatinib, 
oxaliplatin, lamotrigine, salbutamol, prostaglandin E2, quercetin, and ethidium have all 
been reported as substrates (Dickens, et al., 2012, Glaeser, et al., 2014, Kimura, et al., 
2002, Lee, et al., 2009, Salomon, et al., 2015, Takeda, et al., 2002, Thomas, et al., 
2004, Yonezawa, et al., 2006). The fact that they did not induce efflux any of the 
radiolabeled probe substrates employed in the assay suggests that their interaction with 
hOCT1 is substrate-dependent.  
Substrate-dependent interactions were observed with those test compounds 
which were determined to be substrates, as well. Several substrates induced efflux of 
radiolabeled MPP+ and serotonin, but not TEA (Figure 3.3), indicating an interaction at 
the MPP+ binding site but not the TEA pocket. And, even within this group of 
compounds, there appears to be variation in the magnitude of efflux between probe 
substrates. However, these differences cannot necessarily be attributed to differences 
in substrate affinities. Some of these interactions are corroborated by previous reports. 




serotonin, but not TEA, was a more potent inhibitor of MPP+ than of TEA in a study by 
Nies, et al., (2008) characterizing berberine transport by hOCT1. 
In this study, the CCF assay proved useful in identifying substrate-dependent 
modulation, though limitations exist. Due to the nature of the assay, wherein an 
extracellular substrate is exchanged with a cytoplasmic substrate, substrate-dependent 
effects cannot be observed for test compounds which are exclusively inhibitors, as they 
would not induce efflux of probe substrates. To determine substrate-dependent 
interactions with hOCT1 inhibitors, inhibition studies must be completed analyzing 
inhibitors versus multiple substrates. However, in this study, test compounds which had 
previously only been described as inhibitors (diphenhydramine and fluoxetine) and 
compounds which had never been reported and were not expected to interact with 
hOCT1 (BSP) were identified as novel substrates (Figure 3.3). 
The observation that BSP induced efflux of any of the probe substrates, let alone 
all three (Figure 3.3), was particularly unexpected. BSP was selected as a negative 
control for hOCT1 CCF assays because it possesses a negative charge (-2). To date, 
hOCT1 was thought to transport only positively-charged or neutral compounds 
(Koepsell, 2015, Nies, et al., 2011b), but not negatively-charged compounds. Therefore, 
it was believed that the negative charge associated with BSP would prevent its 
interaction with hOCT1. However, as is evident in Figure 3.3, BSP induced efflux of 
each of the probe substrates, which suggests that it is a hOCT1 substrate. To confirm 
that BSP is a substrate, direct uptake was measured. HEK-hOCT1 cells demonstrated 
significant uptake of BSP compared to HEK-EV cells, and time-dependent uptake was 




analysis was completed. The Km and Vmax were determined to be 13.6 ± 2.6 µM and 
55.1 ± 4.1 pmol/mg protein/min, respectively (Figure 3.4C), indicating that hOCT1 is a 
high affinity, but low capacity transporter of BSP. This appears to be the first negatively-
charged substrate characterized for hOCT1, and the implications of this are noteworthy; 
perhaps the most significant: a negatively-charged substrate for hOCT1 may call into 
question its classification as a cation transporter and the mechanism of transport 
established shortly after its cloning (Gorboulev, et al., 1997, Zhang, et al., 1997b). More 
work must be done to elucidate the mechanism of transport of a negatively-charged 
substrate for hOCT1. 
Interestingly, several test compounds previously reported as hOCT1 substrates, 
including imatinib, lamotrigine, and prostaglandin E2, did not induce efflux of any probe 
substrate in the CCF assay (Figure 3.3). Controversy exists regarding the status of 
imatinib and prostaglandin E2 as OCT substrates (Harlfinger, et al., 2005, Hu, et al., 
2008, Kimura, et al., 2002, Nies, et al., 2014, Thomas, et al., 2004, White, et al., 2006). 
Our data may add further strength to the argument that imatinib and prostaglandins are 
not substrates for hOCT1. In our model, lamotrigine docked closest to the “MPP+ 
binding site,” however, it did not appear to overlap with any of the docked probe 
substrates (Figure 3.6). Therefore, it is possible that the lack of overlap causes a 
change in conformation within the translocation pathway that prevents exchange of 
probe substrates for CCF. 
The observed interactions in the CCF assay could be attributed to differential 
binding regions for specific ligands. It has been proposed that hOCT1 contains multiple 




Ciarimboli and Schlatter, 2005). As indicated above, our homology model appears to 
align closely with previously published models. Amino acids reported to interact with 
ligands in previous reports, including C36, F244, S358, I446, C473, D474, also outlined 
the binding regions identified in our docking studies. However, the model produced by 
Chen, et al., (2017) appeared to contain two distinct binding sites, while our model 
suggests a third binding site. This discrepancy may be due, in part, to the fact that 
Chen, et al., (2017) pre-determined the two putative binding sites and subsequently 
docked ligands into both sites, selecting the site which yielded the most favorable score 
as the binding site for that ligand. However, our docking studies allowed for docking 
ligands anywhere within the transporter, and therefore allowed for the distinction of 
three binding pockets. 
As discussed previously, MPP+, TEA, and acyclovir docked within the 
translocation pore, but in disparate locations (Figure 3.7). Accordingly, we termed these 
pockets the “MPP+ binding pocket,” the “TEA binding pocket,” and the “acyclovir binding 
pocket.” A majority of the test compounds docked seemed to dock within one of these 
pockets, with some overlap. Many of the docked substrates docked in or around the 
MPP+ binding pocket, a handful docked within the TEA and acyclovir pockets, and two 
ligands, imatinib and ritonavir, spanned the entire translocation pore. Principal 
component analysis indicated that the MPP+ pocket allows for greater flexibility in ligand 
binding, as there were no specific trends in docked-ligand properties, other than a 
tendency to be smaller in size and ionizable, trends that held true for both endogenous 
ligands and drugs examined in this study. Conversely, ligands docked in the acyclovir 




rotatable bonds) molecules. No trends emerged when relating ligand properties to the 
TEA pocket; however, interestingly, all of the ligands which docked in or near the TEA, 
berberine, cimetidine, and lamivudine, did not induce any efflux of radiolabeled TEA in 
the CCF assay, even though they are substrates of hOCT1 (Hendrickx, et al., 2013, 
Minuesa, et al., 2009, Nies, et al., 2008). This may suggest an occlusion of this site, 
either by TEA or the test compounds, which prevents substrate exchange. Ligands that 
spanned both the TEA and MPP+ binding sites (imatinib and ritonavir) tended to be 
larger ligands dominated by H-bond donors, with a high clogP and a large number of 
rotatable bonds. Notably, a similar GRID docking score was associated with ligands that 
occupied both the MPP+ and TEA pockets. The fact that these molecules effectively 
spanned the entire translocation pore may explain why they function more as inhibitors 
of hOCT1 rather than substrates, as recent reports suggest is the case for imatinib (Hu, 
et al., 2008, Nies, et al., 2014). BSP was an outlier in all cases, largely due to the nature 
and location of its unique binding pocket, lying outside of the translocation channel. 
While the number of test compounds employed in this study is small and doesn’t 
allow for development of concrete conclusions, it could be considered a proof of 
principle study, and as such, certain trends were uncovered which can be followed-up 
on in larger future studies. Despite the small sample size, clear substrate-dependent 
interactions were observed in our CCF assay, confirming substrate-dependent effects 
for hOCT1. The observed substrate-dependent effects strengthen the argument for 
investigating multiple probe substrates in preclinical transport studies to improve 
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Organic cation transporters (OCTs) are a subset of the SLC22 superfamily of 
transporters which mediate the uptake of a wide variety of structurally dissimilar 
charged and uncharged compounds, and as such play a pivotal role in absorption, 
disposition, and excretion of endogenous and exogenous molecules (Koepsell, 2013). 
OCT1, a member of this family, was first identified in rat kidney, and shortly thereafter in 
human liver (Gorboulev, et al., 1997, Grundemann, et al., 1994, Zhang, et al., 1997b). 
Since their cloning, many substrates have been identified for both rat and human OCT1, 
and there is a wide overlap in transported substrates (Dresser, et al., 2001, Jonker and 
Schinkel, 2004, Koepsell, et al., 2003, Koepsell, et al., 2007). However, despite the 
similarities in amino acid sequence between the two transporters, significant differences 
in substrate affinity have been observed (Table 4.1). 
Because of the diverse chemical structures of substrates transported by OCTs, 
the mechanism of substrate recognition, binding, and translocation has been of 
particular interest to the field. Putatively, OCTs contain twelve alpha-helical 
transmembrane (TM) domains, with a large extracellular loop domain situated between 
TM 1-2 and an intracellular loop located between TM 6-7 (Meyer-Wentrup, et al., 1998). 
Recent publications described a potential role for the extracellular loop domain of OCT1 
in substrate affinity and translocation. Keller et al., (2011) demonstrated a decrease in 
affinity and transport efficiency of multiple substrates when mutations were introduced 
within the extracellular loop of rat OCT1. Furthermore, Kerb, et al., (2002) functionally 




Table 4.1. Affinities of select substrates of rat and human OCT1. 
Substrate 
Affinity (Km [µM]) 
 
 
Human OCT1 Rat OCT1 References 
MPP+ 35 9.6 
Boxberger, et al., 2014, Busch et 
al., 1996b 
TEA 168, 229 95 
Bednarczyk, et al., 2003, Nies, et 
al., 2011b, Otsuka, et al., 2005, 
Grundemann, et al., 1994 
Serotonin 197 37.6 
Boxberger, et al., 2014, Busch, 
et al., 1996a 








Transport of dopamine by human OCT1 was demonstrated by Boxberger, et al., (2014), 






Their study identified two mutations, R61C and C88R, located in the extracellular loop 
domain of human OCT1, that negatively impact the transport of model cation MPP+. 
Taken together, these studies suggest that the extracellular loop region of OCT1 may 
indeed play a role in substrate binding and initiating translocation, and this, therefore, 
may be the driving force behind the observed differences in substrate affinity between 
species. 
Structural characterization of OCTs has thus far proven somewhat difficult. 
Because of the largely hydrophobic nature of the transmembrane protein, OCTs have 
yet to be successfully crystalized, making determination of binding regions nearly 
impossible. In lieu of utilizing crystal structures for identifying key binding regions in drug 
transporters, homology modeling and mutagenesis techniques have been employed. 
One such method of exploring key binding regions within a transporter is the generation 
of chimeric transporters. In 2009, Gui and Hagenbuch developed mutagenic chimeras 
of organic anion transporting polypeptides (OATP) 1B1 and 1B3, members of the SLCO 
family, to identify TM 10 as a critical region for the function of OATP1B1. Furthermore, 
Gorboulev, et al., (2005) generated rat OCT1/OCT2 chimeras, and were able to 
demonstrate that exchanging three key amino acids in TM 10 raised the affinity of 
rOCT1 for corticosterone to that of rOCT2. By the same token, human and rat OCT1 
loop chimeras could be employed to examine the role of the extracellular loop domain in 
substrate recognition, binding, and translocation, and determine if the loop domain is, at 
least in part, responsible for the observed differences in substrate affinity between rat 




extracellular loop chimeras, as depicted in Figure 4.1, to functionally characterize the 
role of the loop region in substrate affinity and translocation. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Materials 
The rat OCT1 ORF, cloned into pCMV6-Entry expression vector, was purchased 
from Origene (Rockville, MD). The TOPO TA cloning kit, Taq polymerase, T4 DNA 
ligase, and all chemically competent bacteria were purchased from Invitrogen 
(Carlsbad, CA). Loading buffers, restriction enzymes, and Phusion-HF polymerase were 
purchased from New England Biolabs (Ipswich, MA). DNA ladders, dNTPs, and alkaline 
phosphatase were purchased from Fermentas (Waltham, MA). QuikChange Site-
Directed Mutagenesis kit and Pfu Turbo polymerase were purchased from Agilent 
Technologies (Santa Clara, CA). LB agar powder and ethidium bromide were 
purchased from Fisher Scientific (Hampton, NH). LB broth powder, tris-acetate-EDTA 
(TAE), and tris-borate-EDTA (TBE) buffers were purchased from Sigma-Aldrich (St. 
Louis, MO). All antibiotics were purchased from Amresco, LLC (Cleveland, OH). 
Agarose was purchased from Bio-Rad (Hercules, CA). Gel purification kits and PCR 
clean-up kits were purchased from Qiagen (Valencia, CA). Isopropyl β-D-1- thiogalacto- 
pyranoside (IPTG) was purchased from Gold Biotechnology (St. Louis, MO). X-gal was 

















Figure 4.1. Schematic representation of human and rat OCT1 chimeric proteins. In 
order to examine the role of the extracellular loop (ECL) domain in substrate recognition, 
binding, and transport, chimeric human (C) and rat (D) OCT1 proteins were designed 
from  human (A) and rat (B) wild-type OCT1 proteins by exchanging the ECL regions. For 
the purpose of these studies, the extracellular loop domains are defined as amino acids 
47-153 for rat OCT1, and 46-152 for human OCT1, as described by Grundemann, et al., 







4.2.2 Primer Design 
Primer sequences were designed based on the SLC22A1 coding sequences for 
human (NCBI reference sequence: NM_003057.2) and rat (NCBI reference sequence: 
NM_012697.1) using the BioEdit sequence alignment tool, and the Agilent Genomics 
BioCalculators Tm calculator. All primers were purchased from Integrated DNA 
Technologies, Inc. (Coralville, IA). Primer sequences are listed in Table 4.2. 
 
4.3 RESULTS 
4.3.1 Generation of Human and Rat OCT1 Chimeric Proteins 
In order to determine if disparities observed in substrate affinities between 
human and rat OCT1 are indeed due to the extracellular loop domains, human/rat 
OCT1 chimeric proteins needed to first be developed. Figure 4.2 depicts a schematic of 
the proposed generation of both human and rat OCT1 chimeric transporters. The 
method proposed for mutation of wild-type human and rat OCT1 was overlap extension 
PCR, adapted from Protocol 6 in Sambrook and Russell’s Molecular Cloning, volume 2 
(2001). Looking forward, however, it would be necessary to accurately quantitate and 
compare expression levels of both chimeras and wild-type transporters. Thus it was 
necessary to introduce an affinity tag to each construct before generating the chimeric 
proteins. Addition of an affinity tag, such as a polyhistidine-tag, would allow for 
quantification of the expressed transporters, via Western blot detection, using a single 





Table 4.2. Oligonucleotide primer sequences for addition of C-terminal His-tag to wild-






OCT1 SDM C-term 
His-tag Fwd 
5’- CCC TCG GGC ACC CAC CAC CAC CAC 
CAC CAC TGA CTC GAG TCT AGA -3’ 
QuikChange 
2 
OCT1 SDM C-term 
His-tag Rev 
5’- TCT AGA CTC GAG TCA GTG GTG GTG GTG 
GTG GTG GGT GCC CGA GGG -3’ 
QuikChange 
3 
F-hOCT1 Cterm 6xHis 
(HindIII) 
5’- TTA AAG CTT ATG GTG GAT GAC ATT CTG 
GAG CAG GTT GGG GAG -3’ 
Insert via restriction 
site/TOPO cloning 
4 
R-hOCT1 Cterm 6xHis 
(BamHI) 
5’- TAT GGA TCC TCA GTG GTG GTG GTG GTG 
GTG GGT GCC CGA GGG TTC TG -3’ 
Insert via restriction 
site/TOPO cloning 
5 
F-rOCT1 Cterm 6xHis 
(HindIII) 
5’- TTA AAG CTT ATG CCC ACC GTG GAT GAT 
GTC CTG GAG CAA GTT GGA GAG -3’ 
Insert via restriction 
site/TOPO cloning 
6 
R-rOCT1 Cterm 6xHis 
(BamHI) 
5’- TAT GGA TCC TCA GTG GTG GTG GTG GTG 
GTG GGT ACT TGA GGA CTT GCC TG -3’ 
Insert via restriction 
site/TOPO cloning 
7 
F-hOCT1 Chis HindIII 
6bp tail 
5’- ATA TTA AAG CTT ATG CCC ACC GTG GAT 
GAC ATT CTG GAG CAG GTT GGG GAG -3’ 




R-hOCT1 Chis BamHI 
6bp tail 
5’- TTA TAT GGA TCC TCAA GTG GTG GTG 
GTG GTG GTG GGT GCC CGA GGG TTC TG -3’ 




F-rOCT1 Chis HindIII 
6bp tail 
5’- ATA TTA AAG CTT ATG CCC ACC GTG GAT 
GAT GTC CTG GAG CAA GTT GGA GAG -3’ 




R-rOCT1 Chis BamHI 
6bp tail 
5’- TTA TAT GGA TCC TCA GTG GTG GTG GTG 
GTG GTG GGT ACT TGA GGA CTT GCC TG -3’ 























  Figure 4.2. Generation of human and rat OCT1 chimeric proteins. A schematic of the 
planned generation of human (A) and rat (B) extracellular loop chimeras. The scheme 
depicts mutations of the extracellular loop domains, defined as amino acids 47-153 for rat 
OCT1 (Grundemann, et al., 1994), and 46-152 for human OCT1 (Gourbulev, et al., 1997), 
of each transporter by the overlap extension PCR method. Primers 1 (A) and 10 (B) match 
the beginning sequence of the first transmembrane (TM) domain of their respective 
transporters. Primers 2 and 11 consist of a sequence matching the end of TM1 of their 
respective proteins, followed by a sequence which overlaps with the loop region of the 
opposite protein. Performing PCR with these primers (step 1a) yields a DNA sequence 
corresponding TM1 of one transporter and an overlapping region of the loop domain of the 
other transporter. Primers 3 and 8 consist of sequences matching the beginning of the 
loop domain of one transporter, preceded by a sequence which overlaps with the end of 
TM1 of the opposite protein. Primers 4 and 9 contain sequences that match the end of the 
loop region for their respective transporters. PCR products resulting from these primers 
(step 1b) consist of a small portion of the end of TM1 from one transporter, and the 
complete loop domain of the other. Combining these two PCR products, and melting, 
reannealing, and extending them (step 2) yields DNA sequences containing the complete 
TM1 of one transporter followed by the complete loop domain of the other transporter. 
Similar processes are performed to combine the previous DNA product with TMs 2-12 
(steps 3-5). Following generation of the mutant sequences, restriction digest (primers 
1,7,10, and 14 contain added 5’ restriction sites) and ligation into pcDNA5/FRT vector are 





binding affinities for multiple primary antibodies. Based on success of cloning with other 
transporters (Gui and Hagenbuch, 2009), a polyhistidine-tag (6xHis-tag) was selected. 
4.3.2 Insertion of His-tag into Human and Rat OCT1 DNA Sequences 
Several methods were employed to introduce a His-tag into wild-type human and 
rat OCT1. The first method involved the QuikChange II Site-Directed Mutagenesis kit 
(AgilentTechnologies, Santa Clara, CA). Primers were designed to overlap with the end 
sequence of each wild-type protein, with an insertion of six repeating histidine codons 
between the end of the protein coding sequence and the stop codon (primers 1-2, Table 
4.2). The codon ‘CAC’ was selected for histidine based on codon bias in mammalian 
expression systems (Lavner and Kotlar, 2005). PCR reactions with the QuikChange II 
kit did not yield a product of appropriate size (Figure 4.3). It is likely that the 
complementarity of overlapping primers led to primer-dimer formation, meaning the 
primers annealed to each other and not the DNA template as desired, and thus no 
product is visible within the size range observed. Following multiple attempts, this 
method was abandoned. 
Addition of the His-tag by inclusion in PCR primers, followed by insertion into the 
expression vector via restriction sites was attempted next. Primers were designed for C- 
terminal His-tag insertion into both human and rat OCT1 (primers 3-4 and 5-6, Table 
4.2). Primers included 5’ HindIII and 3’ BamHI restriction sites for subsequent 
subcloning into the pcDNA5/FRT expression vector. PCR product for both constructs 
(human/rat OCT1-Cterm-His) was successfully produced via this method (Figure 4.4), 





500 bp ─ 
1000 bp ─ 
3000 bp ─ 
Lane:  1        2         3          4        5 
6000 bp ─ 
Figure 4.3. PCR products from QuikChange II Site-Directed Mutagenesis kit method. 
Products from PCR using primers and pWhitescript (control) template DNA from the 
QuikChange II kit, and primers 1-2 and human OCT1 WT DNA coding sequence template 
were separated by electrophoresis on a 0.8% agarose in TBE gel. Lane 1: 100 bp ladder. 
Lane 2: 1 kb ladder. Lane 3: pWhitescript control PCR products (expected amplicon size: 
4.5 kb). Lane 4: hOCT1-C-term-His insertion PCR products (5 ng template DNA; expected 
amplicon size: 6.8 kb). Lane 5: hOCT1-C-term-His insertion PCR products (20 ng template 







1000 bp ─ 
3000 bp ─ 
Lane:  1            2           3       
6000 bp ─ 
Figure 4.4. PCR amplicons for human and rat OCT1-Cterm-His. PCR products 
generated from primers 3-4 and 5-6, flanking the coding sequence of human/rat WT 
OCT1, which included a C-terminal His-tag and HindIII and BamHI restriction sites. 
Products were separated by electrophoresis on a 1% agarose in TBE gel. Lane 1: 1 kb 
ladder. Lane 2: rOCT1-Cterm-His amplicon (expected amplicon size: 1.7 kb). Lane 3: 





expression vector, and transform chemically competent E. coli failed to yield any 
bacterial colonies containing human or rat pcDNA5/FRT-OCT1-Cterm-His. The only 
bacterial colonies observed following ligation and transformation attempts contained 
only pcDNA5/FRT empty vector (Figure 4.5), and frequently, no colonies formed. To be 
sure that enough base pairs were present around the restriction sites for enzymes to 
bind and digestion to occur, primers were redesigned to include an additional six base 
pairs outside the restriction sites (primers 7-10, Table 4.2). PCR amplicons were 
successfully generated with these primers, but subsequent subcloning steps again 
yielded no complete constructs. Several alterations were made to the protocols 
provided by manufacturers (summarized in Table 4.3), but all attempts to obtain His-
tagged OCT1 constructs via this method were unsuccessful. Possible reasons for this 
are outlined in the discussion section of this chapter (section 4.4).  
The third subcloning method selected was the TOPO® TA Cloning® kit 
(Invitrogen, Carlsbad,CA). TOPO® cloning, touted as one of the fastest, easiest 
methods of subcloning, involves insertion of a PCR product containing 3’ adenine (A) 
overhangs into the pCR2.1-TOPO® vector with the aid of covalently attached 
topoisomerases. Primers 3-4 and 5-6 were used to generate fresh OCT1-Cterm-His 
PCR amplicons using proofreading polymerase Pfu Turbo (Agilent Technologies, Santa 
Clara, CA), which were then incubated with Taq polymerase to add 3’-A overhangs, as 
prescribed by the manufacturer’s protocol. These PCR products were subsequently 
incubated with the TOPO® vector for ligation, and transformed into chemically 





Lane:  1     2    3     4     5    6     7     8    9    10   11  12  13   14  15   16  17  18   19 
6000 bp ─ 
3000 bp ─ 
1000 bp ─ 
Figure 4.5. DNA isolated from bacterial colonies following ligation of pcDNA5/FRT 
and human and rat OCT1-Cterm-His. Chemically competent TOP10 E. coli were 
transformed with DNA products generated by ligating digested human and rat OCT1-Cterm-
His amplicons and digested pcDNA5/FRT vector. Transformants were grown overnight at 
37°C on LB agar plates containing ampicillin. Colonies were selected, and grown overnight 
at 37°C in LB broth with ampicillin. DNA was isolated from overnight cultures using the 
Qiagen mini-prep kit. A portion of DNA isolated from each colony was digested using HindIII 
and BamHI, then whole and digested DNA were separated by electrophoresis on a 1% 
agarose in TBE gel. Expected bands: 6.7 kb (undigested); 5 kb and 1.7 kb (digested). Lane 
1: 1 kb ladder. Lane 2: Colony1 (rat). Lane 3: Colony 1-digested. Lane 4: Colony 2 (rat). 
Lane 5: Colony 2-digested. Lane 6: Colony 3 (rat). Lane 7: Colony 3-digested. Lane 8: 
Colony 4 (rat). Lane 9: Colony 4-digested. Lane 10: 1 kb ladder. Lane 11: Colony 9 
(human). Lane 12: Colony 9-digested. Lane 13: Colony 10 (human). Lane 14: Colony 10-
digested. Lane 15: Colony 11 (human). Lane 16: Colony 11-digested. Lane 17: Colony 12 





Table 4.3. Troubleshooting of subcloning methods for generating human and rat 
pcDNA5/FRT-OCT1-Cterm-His. 
Alteration to Method Result 
Used purified DNA products from both PCR clean-
up kit and gel purification kit, as well as unpurified 
DNA products in ligation reactions 
No colonies 
Purchased new, and changed brands of restriction 
enzymes (New England Biosciences, Fermentas 
Fast Digest) 
No colonies 
Redesigned primers to include extra base pairs 
around restriction sites to enable proper digestion 
PCR successful, colonies contained 
only pcDNA5/FRT 
Dephosphorylated digested vector before ligation No colonies 
Tried several vector:insert ratios for ligation (1:1, 
1:3, 1:5, 1:9, 1:10 
1:5 yielded colonies containing only 
pcDNA5/FRT; other ratios yielded no 
colonies 
Varied ligation reaction time (1 hour-overnight) No colonies 
Varied ligation reaction temperature (4-25ºC) No colonies 
Purchased new T4 DNA ligase No colonies 
Changed cell type transformed (TOP10, TOP10F’, 
DH5α) 
No colonies 









enzymes and ligation into pcDNA5/FRT vector. Each attempt at TOPO® cloning human 
OCT1-Cterm-His yielded no bacterial colonies following transformation. One attempt at 
TOPO® cloning rat OCT1-Cterm-His yielded several colonies (white and blue; Figure 
4.6A). Eight white colonies were selected for overnight cultures. DNA isolated from 
these colonies was digested with EcoRI. EcoRI was selected due to the presence of 
EcoRI restriction sites flanking the gene insertion site on the pCR2.1 vector, thus 
eliminating the need for double digestion at this step. Digestion of isolated DNA with 
EcoRI yielded two DNA segments, one near 1.2 kb and one around 5.5 kb, when 
separated by gel electrophoresis (Figure 4.6B). The insert of interest, rat OCT1-Cterm-
His, is approximately 1.7 kb, and pCR2.1 empty vector is 3.9 kb. Because the sizes of 
the generated fragments did not match what was expected, this result was somewhat 
confusing. Utilization of the NEBcutter tool (New England Biolabs, Ipswich, MA) 
identified an EcoRI cut site within the rat OCT1 coding sequence at base pair 1159. 
Further analysis demonstrated that the two fragments were likely derived from the 
original rat OCT1 template, pCMV6-Entry-ratOCT1-WT. There is an EcoRI restriction 
site near the beginning of the gene insertion location on the pCMV6-Entry vector. When 
combined with the EcoRI restriction site within the rat OCT1 coding sequence, digestion 
with EcoRI would yield the two observed fragments. pCMV6-Entry also contains a 
kanamycin resistance gene, the antibiotic used for selection with the TOPO® cloning kit. 
Therefore, it was determined that these colonies contained only rat OCT1 template 
vector (pCMV6-Entry-ratOCT1), and not pCR2.1-ratOCT1-Cterm-His, and therefore 
TOPO® cloning failed for both human and rat OCT1-Cterm-His. Subsequently, 











Lane:  1     2    3   4     5    6    7     8    9   10   11  
1000 bp 
Figure 4.6. TOPO® cloning of rat OCT1-Cterm-His. (A) Following TOPO® cloning or 
rat OCT1-Cterm-His, chemically competent TOP10F’ E. coli were transformed with 2 µL 
of the cloning reaction, spread on an LB agar plate containing kanamycin for selection, 
and IPTG and X-gal for blue-white screening, and incubated overnight at 37°C. Colonies 
observed following overnight incubation are circled.  (B) Eight colonies were selected 
from the LB agar plate and grown in overnight cultures. DNA was isolated from the 
overnight cultures by mini-prep and digested with EcoRI, then separated by 
electrophoresis on a 1% agaose in TBE gel. Lane 1: 1 kb ladder. Lane 2: TOPO® cloning 
reaction. Lane 3: rat OCT1-Cterm-His amplicon. Lane 4: Colony 1. Lane 5: Colony 2. 
Lane 6: Colony 3. Lane 7: Colony 4. Lane 8: Colony 5. Lane 9: Colony 6. Lane 10: 







The goal of this study was to investigate the role of the extracellular loop domain 
of OCT1 on substrate affinity by developing and utilizing human/rat chimeric 
transporters. Generation of OCT1 extracellular loop chimeras would allow for the direct 
comparison of substrate affinities associated with whole, wild-type transporters and 
those associated with specific ECL domains, without altering the entire transporter, and 
therefore yield important information regarding the ECL’s role in substrate binding. 
However, in order to be sure that measured transport values are a result of the 
exchange of the ECL, and not due to protein expression, and therefore can be directly 
compared, it was necessary to have a means of accurately quantifying and comparing 
the expression levels of both the wild-type and chimeric transporters. Hence, the need 
for addition of the His-tag to human and rat OCT1. 
There are myriad reasons why subcloning attempts of human and rat 
pcDNA5/FRT-OCT1-Cterm-His were unsuccessful. The first and most obvious potential 
issue surrounds ligation of the gene(s) into the pcDNA5/FRT vector. Although multiple 
alterations were made to manufacturer’s protocols to troubleshoot ligation (summarized 
in Table 4.3), further adjustments could have been made. Due to the size of the gene 
insert, it’s possible that the optimum ratio of insert-to-vector was not achieved, and 
therefore ligation could not occur. To remedy this, more insert-to-vector ratios could be 
tried. Additionally, ligation incubation time and temperature are critical in achieving 
ligation. Further varying the length and temperature of ligation reactions, or changing 
the concentration or type of ligase, may lead to successful ligation, and production of 




ligation reactions) was used in transformation, so varying the amount of DNA added to 
E. coli during transformation procedures may yield colonies. In any case, the 
modifications that can be made to subcloning protocols are infinite, and the cost-benefit 
of continuing the troubleshooting process must be weighed. 
Further causes for the failed subcloning attempts involve properties inherent to 
the gene and bacterial host, rather than subcloning methods. It is possible that the 
mutations introduced into wild-type human and rat OCT1 made the transporters toxic, in 
some way, to E. coli, and therefore inhibited growth of colonies when transformed. 
Toxicity of heterologous proteins, particularly membrane proteins, has been described 
numerous times (Brosius, 1984, Doherty, et al., 1993, Dong, et al., 1995, Dumon-
Seignovert, et al., 2004, Miroux and Walker, 1996, Montigny, et al., 2004). Although in 
this case protein expression was not being induced, it is common for protein expression 
to occur due to the “leaky” lac promoter, which can drive transcription even when not 
stimulated (Nielsen, et al., 2007). Several methods have been proposed to limit toxicity 
resulting from basal expression via the lac promoter. Utilization of a bacterial strain 
which over expresses the lac repressor, lacI or lacIQ, inhibits transcription from the T7 
promoter until induced, and therefore limits basal expression of the heterologous protein 
(Rosano and Ceccarelli, 2014). Additionally, “leaky” expression can be suppressed by 
co-transforming a plasmid which expresses T7 lysozyme, which binds and destabilizes 
T7 RNA polymerase (Moffatt and Studier, 1987, Stano and Patel, 2004), thus 
repressing transcription and eliminating the toxic effects of the heterologous protein. 
Likewise, it is also plausible that the lack of colony growth following 




transporters. The mutations introduced into wild-type human and rat OCT1 may have 
introduced or uncovered a cryptic promoter, a normally silent promoter that when 
activated can lead to transcription and translation of aberrant peptides (Hennig and 
Fischer, 2013, Islam, et al., 2011). Previous reports describe just such an event during 
cloning of other genes (Jakab, et al., 1997, Li, et al., 2011, Saida, et al., 2006), and 
interestingly, a cryptic bacterial promoter was identified within the coding sequence of 
the mouse Mdr1 (P-gp) gene (Pluchino, et al., 2015). Suppression of cryptic promoters 
can be achieved by introduction of Rho-independent transcription terminators (T1 and 
T2) into the vector (Brosius, 1984, Brown and Campbell, 1993, Saida, et al., 2006), 
eliminating the production of the toxic peptides. 
Affinity-tagged OCT1 (rat and human) constructs have been described in the 
literature, however most contain a FLAG- (DYKDDDK) tag (Egenberger, et al., 2012, 
Keller, et al., 2008, Popp, et al., 2005). Only one group, in two separate publications, 
has described the inclusion of a His-tag in an OCT1 expression construct. Keller and 
colleagues (2008, 2011) inserted full-length, wild-type rat OCT1 into the pET21a vector, 
which contains a His-tag sequence a few amino acids downstream of the gene insertion 
site. Our attempts at cloning OCT1-Cterm-His placed the His-tag immediately following 
the OCT1 coding sequences. The inclusion of several amino acids between the end of 
the OCT1 coding sequence and His-tag may be enough of a difference to overcome 
any possible toxicity to transformed bacteria, and allow for colony formation and plasmid 
isolation. 
Had we been able to successfully subclone the His-tag and generate the 




in substrate affinity. If this were the case, we would have expected to see a switch in 
substrate affinities that correlated with the exchange of human and rat OCT1 ECLs 
similar to that observed by Gorboulev et al., (2005) when they exchanged amino acids 
in rat OCT1 for those of rat OCT2, as described in the introduction of this chapter. 
However, because the ECLs of human and rat OCT1 share approximately 80% 
homology, it is possible that significant differences would not be observed between wild-
type and chimeric transporters. In this case, it may be still be possible to study the role 
of the ECL domain’s role in substrate binding and affinity by generating a “loopless” 
mutant. To achieve a “loopless” mutant, we would simply replace the ECL on human 
and/or rat OCT1 with the linker region of a close bacterial homolog, lactose permease, 
or LacY (Abramson, et al., 2003). Interestingly, there is literature precedent for a 
“loopless” mutant of OCT1. Shortly after the initial cloning and characterization of rat 
OCT1, Zhang et al., (1997a) isolated an mRNA splice variant of OCT1 from rat kidney, 
dubbed rOCT1A, which lacked the first two TMs and extracellular loop. When 
expressed in Xenopus laevis oocytes, rOCT1A demonstrated saturable and inhibitable 
transport of model cation TEA, though with altered kinetics. The Km for rOCT1A 
transport of TEA was determined to be 42 µM, whereas the established Km for wild-type 
rat OCT1 TEA transport is 95 µM (Grundemann, et al., 1994). Therefore, while the loop 
is not essential for transport, it appears to be involved in substrate binding and affinity. 
Further characterization of a “loopless” mutant may provide critical insight into the 
structure-function relationship of OCT1. 
While generation of OCT1 chimeric proteins proved too difficult at this time, there 




As demonstrated by others, important data relating to substrate binding, affinity, and 
translocation, as well as structural insights may be obtained from studies with chimeric 
transporters. And because OCT1 has a solidly established role in the ADME and 
efficacy of several clinically important drugs, it would be worthwhile for these to be 

















Drug-drug interactions (DDIs) resulting from the concurrent use of multiple 
medications are increasing, particularly in the geriatric population. One report estimates 
that nearly 10% of emergency department visits are the result of adverse drug events 
(ADEs), which include DDIs (Maher, et al., 2014). DDIs can occur through several 
processes in the body, including drug absorption, distribution, metabolism, and 
excretion, as discussed in Chapter 1. Most frequently, DDIs occur during metabolism, 
as a result of unfavorable interactions with cytochrome P450 enzymes. However, there 
is a growing appreciation for the role of drug transporters in DDIs, as DDIs often occur 
at the transporter level. As such, government-issued guidelines now include 
recommendations for screening INDs for transporter-mediated DDIs (European 
Medicines Agency, 2012, U.S. Food and Drug Administration, 2017). These guidelines 
recommend including OATPs, OATs, and OCTs, among others, in preclinical studies. 
hOCT1, expressed primarily in the liver, interacts with more than 100 clinically-
prescribed drugs (Nies et al., 2011), and thus serves as an important target for 
transporter-mediated DDIs. While there is much information available regarding hOCT1 
interactions with xenobiotics, little information is available regarding endogenous roles 
for the transporter. Endogenous function is equally important to consider when 
identifying ADEs. Furthermore, several reports demonstrate substrate-dependent 
effects for close relatives of hOCT1 (Belzer, et al., 2013, Martínez-Guerrero and Wright 
2013, Roth, et al., 2011, Zhang, et al., 2013), and suggest the same for hOCT1. 




structural information is available, making it challenging to define ligand binding 
domains and predict unfavorable drug interactions. 
Without a comprehensive understanding of the structure and mechanisms of 
ligand interaction with hOCT1, identification and prevention of DDIs involving this 
transporter remains difficult. Therefore, the studies performed in this dissertation were 
designed to address the lack of understanding, on multiple levels, of the mechanisms 
through which adverse drug interactions occur via hOCT1. I formed the central 
hypothesis that both endogenous and xenobiotic compounds modulate the functional 
activity of hOCT1 in a substrate-dependent manner through interaction with specific 
ligand-binding domains within the transporter. This hypothesis was tested via three 
specific aims: 1) investigation of the effect of xenobiotics on endogenous substrate 
transport by hOCT1, 2) identification and characterization of substrate-dependent 
interactions with hOCT1, and 3) examination of the role of the extracellular loop domain 
of hOCT1 in substrate affinity and translocation. The findings resulting from these aims 
are discussed further in the following sections. 
 
5.2  SPECIFIC AIM 1 
For the first specific aim, a role for hOCT1 in transport of monoamine 
neurotransmitters was established. Uptake of radiolabeled serotonin, dopamine, and 
norepinephrine by hOCT1 was determined in a heterologous expression system. Next, 




drugs was examined. And finally, uptake and inhibition studies were completed for 
serotonin in primary human hepatocytes. 
While it is widely accepted that hOCT1 is involved with the clearance of many 
xenobiotics, but an endogenous function of hOCT1 has not been definitively 
determined, though some reports suggest the possibility, particularly for monoamine 
neurotransmitters (Amphoux et al., 2006, Breidert et al., 1998, Busch et al., 1996, 
Jonker and Schinkel, 2004, Kerb et al., 2002, Lips et al., 2005). To confirm a role for 
hOCT1 in neurotransmitter transport, direct transport of radiolabeled serotonin, 
dopamine, and norepinephrine was observed. Of the three, serotonin was by far the 
superior substrate of hOCT1, with only modest transport of dopamine, and very little 
uptake of norepinephrine measured. This was particularly significant because of the 
high levels of serotonin contained within the small intestine, and furthermore in the 
portal blood supply, and the fact that the liver is known to be involved in the clearance of 
up to 70% of circulating serotonin (Thomas and Vane, 1967, Toh, 1954), making 
hOCT1 a potential target for drug-induced inhibition of serotonin clearance. Kinetic 
characterization of serotonin transport determined that hOCT1 is likely a low-to-mid 
affinity but high capacity transporter of serotonin, yielding solid evidence of its role in 
serotonin clearance. 
Increased serotonin uptake into hepatocytes has been implicated in the 
pathogenesis and progression of non-alcoholic steatohepatitis (NASH) (Nocito, et al., 
2007a). Furthermore, OCT1 expression is increased at the mRNA level in a mouse 
model of NASH (Clarke, et al., 2015). If the same is true in human NASH, hOCT1-




hepatocytes or humanized mouse models may aid in fleshing out a role for hOCT1 in 
NASH progression. 
Because hOCT1 is known to interact with many drugs, it is possible that the 
newly discovered endogenous function could be disrupted. To evaluate the potential for 
drug-endogenous substrate interactions, a small drug screen was performed with 
radiolabeled serotonin as the probe substrate. The screen identified multiple 
prescription and over-the-counter drugs as inhibitors of hOCT1-mediated serotonin 
uptake. This was confirmed in primary human hepatocytes, an arguably more relevant 
model. Inhibition of serotonin uptake into the liver effectively increases circulating 
serotonin levels, which bears several implications, many of which were discussed in 
Chapter 2. Further implications of increased circulating serotonin levels involve 
serotonin signaling in both the heart and the bone. Cardiac valve abnormalities, 
including fibrodysplasia and calcification, have been described in patients with carcinoid 
syndrome, due to increased serotonin signaling as a result of excessive serotonin 
secretion from carcinoid tumors in the gut (Levy, 2006). Yadav et al., (2008) described 
misregulation of bone remodeling, leading to osteoporosis, as a result of increased 
serotonin synthesis in the gut consequently increasing serotonin signaling in 
osteoblasts. Drug-mediated inhibition of OCT1 serotonin transport has the potential to 
increase serotonin levels in the blood, which may lead to pathological signaling in 
several tissues, and thus deserves further investigation but was outside the scope of 
this dissertation. 
Studies in this aim also identified putative substrate-dependent interactions, 




5.3  SPECIFIC AIM 2 
Results from experiments completed for aim 1 suggested substrate-dependent 
effects for hOCT; several drugs known to be substrates or inhibitors of hOCT1 did not 
inhibit hOCT1-mediated uptake of serotonin. Therefore, for specific aim 2, we explored 
substrate-dependent effects experimentally and in silico by employing a novel 
competitive-counterflow (CCF) assay and docking ligands into a homology model for 
hOCT1. 
The CCF assay identified several ligands which induced efflux of one or two 
probe substrates, but not all three. Several of these interactions were explained by data 
extracted from the docking studies, which suggested multiple binding pockets within the 
hOCT1 translocation pore. The identification of multiple binding sites in our study 
corroborates hypotheses from several groups that hOCT1 and other OCTs possess a 
large substrate binding region versus a specific binding site, as is common in enzymes 
(Chen, et al., 2017, Ciarimboli, et al., 2004, Ciarimboli and Schlatter, 2005, Koepsell, et 
al., 2003). The existence of multiple binding pockets may complicate the binding 
kinetics of multiple ligands at the same time. One can imagine that the binding of a 
ligand in one site may cause conformational changes within the transporter that occlude 
another ligand from binding in a different site. Indeed, this may explain the lack of efflux 
induced by acyclovir, lamotrigine, salbutamol, and ethidium, which have all been 
reported as substrates, as discussed in Chapter 3. Further mechanistic studies need to 




Another notable finding in the CCF assay was the identification of negatively-
charged BSP as a substrate for hOCT1. As discussed in Chapter 3, hOCT1 is 
considered a transporter of positively-charged and neutral compounds (Koepsell, 2015, 
Nies, et al., 2011b). The identification of a negatively-charged compound not only calls 
into question the nomenclature of the transporter (organic cation transporter), but also 
potentially the mechanism of transport. hOCT1 is described as an electrogenic 
transporter which facilitates the movement of positively charged molecules across cell 
membranes along an electrochemical gradient (Gorboulev, et al., 1997, Koepsell, 2004, 
Zhang, et al., 1997b). While transporting BSP from an extracellular region of high 
concentration to an intracellular location of low concentration would follow the chemical 
gradient, transporting negatively-charged BSP from extracellular space to the cytoplasm 
would mean transporting against the electric gradient (membrane potential) which 
generally requires a source of energy. Organic anion transporting polypeptides (OATPs) 
transport numerous negatively-charged substrates, as the name suggests, and thus 
facilitate the transport of compounds against the electric gradient. It has been 
hypothesized that this is made possible by the fact that OATPs can transport in both 
directions, and therefore exchange extracellular substrates with a negatively-charged 
molecule within the cell, effectively functioning as exchangers, though a counter ion has 
not yet been identified (Roth, et al., 2012). OCTs are also capable of transporting in 
both directions (indeed, this serves as the foundation of the CCF assay; Arimany-Nardi, 
et al., 2014, Lips, et al., 2005, Zhang, et al., 1998), and thus may rely on a similar 
mechanism to transport negatively-charged substrates like BSP. Certainly, more studies 




In our studies, docking ligands into a homology model proved useful, to an 
extent, in explaining substrate-dependent interactions observed in the CCF assay. In 
industry, the employment of docking studies could expedite pre-clinical inhibition studies 
and save money long-term. Docking studies could be employed prior to transporter 
assays to identify potential interactions which can be examined further in the lab, and 
potentially eliminate the need to test a large group of compounds which would not 
demonstrate any significant interactions. However, this is not likely to occur in the very 
near future, as several improvements to modeling large hydrophobic proteins are 
necessary, particularly for flexible, non-static models which require large computing 
capacity. Additionally, improving model accuracy would ideally require a crystal 
structure for hOCT1. Improvement in modeling techniques, and ultimately solving a 
crystal structure for hOCT1 could improve the process of identifying potential 
transporter interactions which could be highly beneficial for drug companies entering 
pre-clinical drug trials. 
 
5.4  SPECIFIC AIM 3 
Substrate-dependent modulation from within the translocation pore was explored 
in aim 2. However, due to unfavorable energetics and intrinsic disorder, the extracellular 
loop (ECL) domain of hOCT1 couldn’t be modeled, a limitation of our homology model. 
Information from several reports suggests that the ECL is important in ligand recognition 




examine the role of the ECL in these interactions, and specific aim 3 attempted to 
address this. 
The goal of specific aim 3 was to generate chimeric transporters containing 
specific regions from both human and rat OCT1 to explore the differences in substrate 
affinities between species. However, this goal proved too lofty to obtain, at least within 
the scope of this dissertation, despite the same having been completed for relatives of 
OCT1 (Gorboulev, 2005, Gui and Hagenbuch, 2009). Putatively, this was due to a toxic 
protein product resulting from insertion of the His-tag at the C-terminus of the 
transporters. Perhaps future attempts at generating tagged constructs could be 
successful by including a FLAG-tag instead of a His-tag. If the histidine codon or series 
of repeating codons employed in our primers to introduce the tag was ultimately what 
lead to a failure of bacterial colonies to grow during subcloning, utilizing a FLAG-tag 
instead of the histidine should allow for colony growth. Conversely, changing the codon 
employed for histidine may yield similar results. For our ultimate purpose of expression 
in a mammalian cell line, the codon CAC was utilized for histidine, as this is this 
optimum codon for mammalian protein expression. The codon CAT could be used in 
place of CAC to encourage colony growth. 
Had we been successful in producing the desired chimeras, uptake studies 
comparing the chimeras with wild-type transporters from both species would have been 
conducted. It was hoped that these studies would yield observable differences in 
substrate affinity that could ultimately be traced back to specific amino acid regions, 
thus highlighting key binding regions. These studies would also determine whether the 




suggested. Additionally, chimeric OCT1 may prove useful in further explaining 
substrate-dependent interactions observed in other aims of this dissertation. 
 
5.5 FUTURE DIRECTIONS 
The studies performed in aim 1 determined that hOCT1 serves an important 
endogenous function, and transport of xenobiotics can disrupt this function. Likely, 
OCTs didn’t evolve to serve as xenobiotic transporters (Nigam, 2015), so determining 
endogenous functions of hOCT1 is critical to preventing adverse drug events relating to 
inhibition of endogenous function. While we have identified one function in serotonin 
clearance, the polyspecificity of hOCT1 might suggest that it serves multiple 
physiological functions. Chen et al., (2016) describe hOCT1 as a high capacity thiamine 
transporter and suggest a role for the transporter in hepatic steatosis, though one could 
argue the authors over-emphasize the implications of hOCT1-mediated thiamine 
transport. In any case, a full understanding of the endogenous roles played by hOCT1 is 
critical to predicting and preventing drug-mediated interruption of endogenous function 
at the transporter level, and as such, further studies are necessary. 
As discussed above, the studies performed for aim 2 identified multiple 
substrate-dependent interactions for hOCT1, as well as potential mechanistic 
explanations for the observations. However, not all of the observed interactions could 
be explained by docking ligands into our model. In our study, ligands were docked into a 
rigid model, meaning that the computer fit the ligands to available space within the 




model which could incorporate transporter movement constraints obtained from 
observations of conformational changes during transport. Techniques such as NMR and 
FRET may be useful in elucidating the structural changes during transport to produce 
such a model. However, laboratory techniques to solubilize the transporter and perform 
such studies must be optimized before such studies could be conducted. Combining a 
flexible transporter model with simultaneous and/or chronological docking of multiple 
ligands may aid in further explanation of several of the interactions observed in Chapter 
3. 
The list of compounds tested in the CCF assays served sufficiently as an 
introductory study in substrate-dependent interactions for hOCT1. However, further 
expansion of the group of test compounds could allow for more information to be 
extracted from the combination of in vitro and in silico methods. If enough compounds 
were screened in a similar fashion to those in this dissertation, one could compile the 
information and develop a pharmacophore model for each binding site identified. A 
similar study was performed by Ahlin, et al., (2008), but for a single substrate, and thus 
a single binding site. Because we have defined multiple binding sites for hOCT1, new 
studies are necessary to identify comprehensive pharmacophore(s) for all binding sites. 
Specific amino acids within hOCT1 have been identified, via mutagenesis 
experiments, as important in binding certain substrates (Gorboulev, et al., 1999, 
Gorboulev, et al., 2005, Popp, et al., 2005). Furthermore, mutants observed in different 
populations demonstrate altered transport of one substrate but not another (Kerb, et al., 
2002), as discussed in section 1.3.5. Therefore, it is possible that hOCT1 variants may 




acids previously identified as important to substrate binding or those that line the 
binding sites identified in aim 2, combined with uptake and inhibition studies could 
elucidate mutants which exhibit altered substrate-dependent effects. 
Ultimately, crystallization of hOCT1 by itself and, ideally, co-crystalized with 
various ligands would yield important structural information with regards to binding sites 
and protein conformation. A hOCT1 crystal structure could guide a multitude of 
structural and SAR studies toward a more comprehensive understanding of substrate 
binding and ligand interactions. 
In conclusion, the studies in this dissertation have identified important functional 
qualities for hOCT1, and attempted to elucidate the underlying structural mechanisms 
involved. Our studies have demonstrated that the current guidelines for preclinical 
determination of potential DDIs should be reassessed. However, much work still needs 
to be completed to obtain a comprehensive understanding of the mechanisms of ligand 
interaction and structure-function relationships for hOCT1, to further aid the goal of 
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